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GENERAL INTRODUCTION 
Many kinds of viruses and bacteria have been associated with respiratory 
diseases of cattle and sheep. Viruses enumerated by Stott et al. (1980) were 
infectious bovine rhinotracheitis (IBR) virus, bovine parainfluenza 3 (BPI-3) virus, 
adenovirus type 3 and bovine respiratory syncytial virus (BRSV). Bacterial 
proliferation and hence pneumonia occurs consistently after prior exposure of the 
lung to other microorganisms particularly viruses (Davies et al., 1986). These 
viruses may suppress resistance mechanisms in the respiratory tract and thereby 
predispose to infection with bacterial agents such as Pasteurella sp. Consequently, 
respiratory disease in cattle and sheep is regarded as having multifactorial etiology. 
Defined clinical syndromes in these species include enzootic pneumonia (calves) 
and ovine pneumonia (sheep), shipping fever, bronchitis and respiratory mucosal 
damage contributing to multifactorial etiology of respiratory tract diseases (Davies 
et al., 1980, 1983; Sharp et al., 1978). 
Bovine PI-3 virus, a member of this respiratory disease complex is 
considered as an important factor in the initiation of such infections (Alley and 
Clarke, 1977). The extent of economic losses due to these infections was 
indicated by several authors (Jensen 1968; and King et al; 1958). The annual loss 
in the United States alone in 1954 was estimated at $25 million (Shaw 1954). Total 
economic losses at present would probably be much greater. 
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Parainfluenza viruses belong to the genus Paramyxovirus of family 
Paramyxoviridae. Other Important viruses Included In this genus are Sendai virus, 
simian vlrus-5 (SV-5), and Newcastle disease virus (NOV) of poultry. These viruses 
are classified together mainly due to the similarities in the properties of their 
structural proteins. Two strains of PI-3 virus have been identified (Abinanti et al., 
1961), one of human (Chanock et al., 1958) and the other of bovine origin 
(Reisinger et al., 1959). The strains cause Infections associated with the respiratory 
tract In of man and cattle respectively (Wenzel et al., 1972; Frank and Marshall, 
1973). These strains have been reported to be closely related but Individual 
antigenic differences are recognized. Vaccination of non-human primates with live 
BPI-3 virus was shown to stimulate antibody production and protection against 
challenge with human PI-3 (HPI-3) virus (Coelingh et al., 1988). HPI-3 virus.also 
shares antigenic determinants with Sendai virus and to a lesser extent with SV-5 
(Ito et al., 1987). However, information on the antigenic relationships of BPI-3 virus 
with Sendai virus and SV-5 is limited. 
The immune status of an animal is an important factor in determining the 
outcome of exposure to BPI-3 virus infection. Protection of young animals against 
various diseases is dependent upon the transfer of maternal antibodies from 
immune cows to their calves through colostrum. The level of maternal antibody 
decreases with age and disappears by 6 to 8 months of age (Sweat, 1968). 
Consequently, the calves at weaning time have lost most of the protection obtained 
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through colostrum and are susceptible to disease. Protection of the animal against 
BPI-3 virus infection is important at this crucial period. 
Modified live virus (MLV) and inactivated virus vaccines against BPI-3 virus 
infection are being used alone or in-combination with other vaccines (Bittle & Muir, 
1989). Inactivated virus vaccines provoke only a humoral immune response and 
the antibodies do not eliminate BPI-3 virus present in upper respiratory tract. 
Another disadvantage of current vaccines is that immunization of young animal is 
not readily accomplished due to the presence of anti-viral antibodies acquired from 
the dam. Vaccines administered by a parenteral route are effectively blocked by 
these maternal antibodies resulting in a very limited immune response (Murphy 
et al., 1989). If vaccination is delayed until maternal antibodies have disappeared, 
the animal can be successfully immunized. However, there is a potential for 
infection to occur prior to Induction of immunity by vaccination. 
The present study was designed to evaluate: 
(1) The recognition of paramyxovirus antigens by lambs. 
(2) The extent of antigenic interrelationships among different paramyxoviruses 
as determined by hemagglutination inhibition (HI) test, enzyme linked 
immunosorbent assay (ELISA), Western immunoblot assay (WIA), and 
radioimmunoprecipitatlon assay (RIPA). 
(3) The effect of maternal antibodies on vaccination and degree of sensitization 
by homologous as well as heterologous virus vaccines. 
(4) 
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protective ability of lieterologous virus against PI-3 virus infection in sheep. 
Explanation of Dissertation Format 
This dissertation consists of a general introduction, a review of literature, two 
parts, a general summary, and literature cited. Each part presents a different 
experiment and is composed of an abstract followed by an introduction, materials 
and methods, results and discussion. 
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REVIEW OF LITERATURE 
The family Paramyxoviridae is composed of three genera namely, 
Paramyxovirus, Morbilllvirus, and Pneumovirus (Kingsbury et al., 1978) and 
includes some of the most important pathogens of domestic animals and humans. 
The genus Paramyxovirus includes mumps virus, human parainfluenza virus 
types 1-4 (HPI-1 to 4), and several animal viruses of which bovine parainfluenza 
type 3 (BPI-3), Sendai virus (SV), simian virus 5 (SV-5) and Newcastle disease virus 
(NOV) are the best characterized. The Morbilllvirus genus consists of measles 
virus (MV), and the non-human animal viruses of canine distemper (CDV), 
rinderpest virus (RPV) of cattle and Peste des Petits ruminants (PPRV) of sheep 
and goat. Bovine and human strains of respiratory syncytial virus (RSV) and 
pneumovirus of mice are classified in the genus Pneumovirus. 
Originally, the classification of family Paramyxoviridae Into subgroups was 
based on the presence of hemagglutination and neuraminidase activities of the viral 
glycoproteins. Paramyxoviruses possess both hemagglutlnating and 
neuraminidase activity; viruses of the genus Morbilllvirus do not contain 
neuraminidase activity while viruses of the genus Pneumovirus lack both of the 
activities. 
Genetic sequencing of the viruses of family Paramyxoviridae has given new 
insight into their interrelationship and increased our understanding of the 
evolutionary diversity of these viruses. Based on sequence homology between 
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corresponding genes, Spriggs et al. (1987) divided the Paramyxoviridae into three 
distinct subgroups. The first group consists of Sendai virus, parainfluenza virus 
type 3, measles virus, and canine distemper virus. The second group contains 
SV-5 and Newcastle disease virus and the third group consists of respiratory 
syncytial virus. Further grouping by antigenic cross reactivity is reported to differ 
from both these classifications (Ito et al., 1987). Immunological interrelationships 
among human and non-human paramyxoviruses have been studied by the 
immunoprecipitation assay (GoswamI and Russell, 1982; Ito et al., 1987). 
Immunological reactivities of various antisera with virus-specific polypeptides of 
paramyxoviruses indicated that Sendai virus, human P11, and human PI-3 belong 
to one antigenic group, and human PI-2, PI-4, mumps virus and SV-5 to a second 
group. Furthermore, the human PI-1, PI-2, PI-3, PI-4 viruses and mumps virus 
formed a single antigenic group which overlap the above groups. Although 
Newcastle disease virus belongs to a separate group it showed some cross 
reaction with the human paramyxoviruses. 
Morphology and Viral Structure 
Paramyxoviruses are enveloped and highly pleomorphic. Although generally 
spherical in shape, ranging in diameter from 150 to 300 nm, filamentous forms are 
commonly observed. These replicate in the cytoplasm and are released through 
the host cell membrane. The genome is a single-stranded, non-segmented RNA 
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molecule with a molecular weight (MW) ranging from 4.6 to 7 x 10® kd. It is 
surrounded by a nucleoprotein (NP) which forms a filamentous, herringbone-like 
nucleocapsid core. Also associated with the nucleocapsid are two minor proteins 
the L (Large) and P (phospho) proteins. Surrounding the nucleocapsid structure is 
the lipid rich envelope containing virus specific projections (peplomers). These 
peplomers are comprised of two glycoproteins, i.e., hemagglutinin and/or 
neuraminidase (HN) and fusion (F) proteins. A schematic model of a 
paramyxovirus Is shown in Figure 1 and some characteristics of the structural 
proteins are presented in the Table I. The major virus-coded structural and non­
structural proteins of paramyxoviruses have been studied. Parainfluenza viruses 
generally contain 6 to 8 structural proteins (Jambou et al., 1985; Wechsler et al., 
1985; Panigrahi et al., 1987). These proteins vary in their MW and functional 
activity. All members of paramyxoviruses contain two surface glycoproteins; a 
fusion (F) protein, and a receptor binding (HN) protein which are anchored through 
transmembrane! domains into the virion envelope. The F protein has fusigenic 
activities at neutral pH (White et al., 1983). This allows direct penetration of the 
virus into a susceptible host cell. This protein is first synthesized as an inactive 
precursor molecule (FQ), which is then modified by proteolytic (cellular proteases) 
cleavage into two subunit polypeptides (F, and Fj) which are held together by a 
disulfide linkage (Scheid and Choppin, 1974, 1977; Scheid et al., 1978). The MW 
of Fo, Fi and Fg is 80 to 63 Kd, 50 Kd and 10 to 20 Kd respectively in HPI-3 
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Actin 
Envelope 
Figure 1. A schematic representation of a paramyxovirus virion. H(N), 
hemagglutinin (Neuraminidase) glycoprotein: F, fusion glycoprotein; 
RNP, ribonucleoprotein; M, matrix (membrane); P, Phosphoprotein; N, 
nucleoprotein; L, large protein (Vianionpaa et al., 1989. Adv.Virus Res. 
37:211-242). 
Table 1. Structural Proteins of Paramyxoviruses 
Protein/designation Molecular 
weight x 10'^ ° 
Chemical nature Location Remarks 
Hemagglutinin (HN H, G) 72-80 Glycosylated Envelope Attachment to host-cell 
receptors; neuraminidase 
and/or hemagglutinating 
activities (HN, H); in 
pneumoviruses both the 
activities are missing (G) 
Fusion (FQ-^FI + FJ) Fo 60-70 
Fi 40-60 
F 2 10-20 
Glycosylated 
Glycosylated 
Glycosylated 
Envelope Fusion, hemolysis; penetration 
Nucleoprotein (NP) 43-70 Phosphorylated Nucleocapsid Bound to RNA 
Phosphoprotein (P) 32-70 Phosphorylated Nucleocapsid Component of polymerase 
complex 
Large (L) -200 Nucleocapsid Component of polymerase 
complex; post-transcriptional 
modifications (?) 
Matrix (M) 28-40 Phosphorylated Inside virion Assembly; regulation of 
transcription 
Actin (A) 43 Inside virion Host-cell origin 
" Extimated by gel elctrophoresis. 
Source: Vianionpaa et al., 1989. Adv. Virus Res. 37:211-242. 
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virus (Elango et al., 1986; Spriggs et al., 1986). The MW of the F protein of 
BPI-3 virus is 55 Kd (Shibuta et al., 1979; Morein et al., 1983; Panigrahi et al., 
1987)- The MW of F protein in Sendai virus and SV-5 is 64 Kd and 66 Kd 
respectively (Santoro et al., 1989; Paterson et al., 1984). There is considerable 
homology at the N-terminal end of all paramyxovirus F proteins (Collins et al., 
1984; Paterson et al., 1984; Tsukiyama et al., 1988). This homology is further 
extended by the alignment of the amino acid sequence of the protein. There is 
43 and 25 percent amino acid homology between F protein of Sendai virus and 
SV-5 when compared with HPI-3 virus (Cote et al., 1987; Spriggs et al., 1986; 
Waxham et al., 1987). Such studies are lacking in BPI-3 virus. 
The receptor binding proteins have biological properties in addition to 
hemagglutination/hemadsorption and neuraminidase activities (Choppin and 
Compans, 1975; Choppin and Scheid, 1980) and these properties are 
associated with different sites on the same glycoprotein (HN) molecule (Orvell 
and Grandien, 1982; Orvell and Norrby, 1977; Portner, 1981; Scheid et al., 
1978; Yewdell and Gerhard, 1982). The presence or absence of HN proteins 
have provided a useful description for classification of paramyxoviruses Into 
three separate genera. The MW of the HN glycoprotein is 69 Kd in BPI-3 virus 
(Shibuta et al., 1979; Morein et al., 1983; Panigrahi et al., 1987), 69 to 72 Kd in 
HPI-3 virus (Jambou et al., 1985; Elango et al., 1986; Spriggs and Collins, 
1986), 69 Kd in Sendai virus (Scheid and Choppin, 1974) and 70 Kd in SV-5 
(Peluso et al., 1977; Hiebert et al., 1985; Alkhatib and Briedis, 1986). The HN 
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glycoprotein has 5-6 asparagine-linked glycosylation sites In paramyxoviruses 
(Waxham et al., 1988). The HN proteins from different members of the genus 
Paramyxovirus share some degree of amino acid sequence homology. The 
HPI-3 virus share 47 and 20 percent amino acid homology with the HN proteins 
of Sendai virus and SV-5 respectively (Elango et al., 1986; Spriggs and Collins, 
1986). The amino acid sequence homology between HN proteins of BPI-3 and 
HPI-3 viruses has not been reported. 
Associated with the inner leaflet of the viral envelope is a non-glycosylated 
matrix (M) protein. Although the role of M protein is not well understood, this 
protein is believed to interact both with nucleocapsid complexes and surface 
glycoproteins In the assembly of mature virions (Heggeness et al., 1982; 
Taffereau and Roux, 1988). The M protein may also function coordlnately in the 
alignment of the surface glycoproteins and assist in the maintenance of their 
conformations (Peeples and Bratt, 1984). The calculated MW of M protein in 
BPI-3 and HPI-3 viruses are 38 Kd and 35 to 40 Kd respectively (Jambou et al., 
1985; Elango et al., 1986; Panigrahi et al., 1987; Spriggs and Collins, 1986). 
The reported MW for the M protein of Sendai virus is 39.5 Kd (Spriggs et al., 
1987) while the MW of the M protein in SV-5 is 38 Kd (Peluso et al., 1977). 
There is 60 percent amino acid sequence alignment between the M proteins of 
HPI-3 and Sendai viruses (Galinski et al., 1987; Luk et al,, 1987). 
In addition to M protein, the viral envelope encloses a nucleocapsid 
complex which consists of the genomic RNA and three associated proteins, a 
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nucleocapsid protein (NP), a phosplioprotein (P) and a large (L) protein 
(Choppin and Compans, 1975; Lamb et al., 1976; Portner and Murti, 1986; 
Portner et al., 1988). The MW of NP, P and L proteins In BPI-3 virus Is 66, 83 
and 180 Kd respectively (Panigrahi et al., 1987). For HPI-3 virus, the MW is 66 
to 68, 83 to 90, and 200 Kd for NP, P and L proteins respectively (Elango et al., 
1986; Spriggs and Collins, 1986). The MW of NP protein in Sendai virus and 
SV-5 is 60 Kd and 61 Kd and that of L protein Is 231 Kd and 200 Kd 
respectively (Morgan and Rakestraw, 1986; Peluso et al., 1977; Scheld and 
Choppin, 1974). These proteins take part in early viral transcription and 
capping, methylation and polyadenylation of early viral mRNA, and in the 
synthesis of positive and negative strand leader sequences (Choppin and 
Compans, 1975; Matsumoto, 1982). 
The paramyxovirus virion also contains cellular actin as a structural 
component (Lamb et al., 1976; Tyrrell and Norrby, 1978). Its function in the 
virion structure is unknown, but actin filaments are known to be involved at all 
stages of the budding process (Bohn et al., 1986). Presumably, actin can 
interact with nucleocapsid and may increase the stability of the virion. 
At least one non-structural protein has been identified in paramyxovirus 
infected cells but not in virions (Lamb et al., 1976; Peluso et al., 1977; Lamb 
and Choppin, 1978; Rima and Martin, 1979; Merrier and Compans, 1982). The 
non-structural protein(s) in different paramyxoviruses have been designated C 
(Lamb et al., 1976) but are sometimes called V (Peluso et al., 1977) or S (small) 
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proteins (Rima and Martin, 1979). No data is available on the functional or 
immunological properties of the non-structural protein(s). 
Antigenic differences in the variants of human and bovine PI-3 viruses 
have been reported. Coelingh et al. (1987) determined HN gene sequence for 
16 antigenic variants of human PI-3 virus. The variants were selected by using 
monoclonal antibodies (MAbs) to the HN proteins. Each variant had a single 
point mutation in the HN gene, coding for a single amino acid substitution in the 
HN protein. Monoclonal antibodies revealed extensive antigenic differences 
between the HN glycoproteins of human and bovine PI-3 viruses (Ray and 
Compans, 1986; Coelingh et al., 1987; Rydbeck et al., 1987; and Klippmark 
et al., 1990). MAbs against HN, F, and NP proteins of BPI-3 and HPI-3 viruses 
in hemagglutination inhibition (HI) tests and ELISA demonstrated marked 
differences between these viruses primarily in the HN protein where up to five 
epitopes differed. One epitope of the F and one of the NP protein also differed. 
Bovine PI-3 was found to be a homogeneous subtype and distinct from human 
PI-3 virus. The nucleoprotein showed the broadest cross-reactions among 
these paramyxoviruses, whereas the matrix (M) polypeptide exhibited antigenic 
individuality. Shibuta et al. (1986), demonstrated the differences in the BPI-3 
virus variants using monoclonal antibodies against viral glycoproteins. There 
were considerable differences between strains relative to the structure of the 
viral envelope proteins. This statement is in contrast with the results reported 
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by Klippmark et al. (1990). This difference in results may be due to variations in 
viral strains and MAbs against these viruses used in their studies. 
Studies were conducted using MAbs directed against SV-5 viral proteins 
to reveal antigenic differences from other paramyxoviruses (Goswami and 
Russell, 1983; Randall et al., 1987). Two different epitopes were detected on 
the SV-5 HN polypeptide, one being specific to SV-5 and the other also 
associated with human PI-2 HN polypeptide since MAbs against the SV-5 NP 
polypeptide also reacted with human PI-2 NP polypeptide. Epitopes showing 
both specific reactivity and group cross reactivity were detected with human 
PI-3 HN and NP MAbs against human PI-3 and Sendai viruses. 
Determinants of Pathogenesis 
The pathogenesis of and immunity to paramyxovirus Infection are not 
known in as much detail as the molecular structure and replication of these 
viruses. Due to lack of information about different aspects of paramyxoviruses, 
examples of other viruses included in the family Paramyxoviridae will be 
provided where appropriate. 
There have been suggested links between possible pathological events 
and various viral proteins. The surface glycoproteins HN and F are important in 
pathogenesis, as each plays a central role in adsorption and penetration. 
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These proteins also possess the main immunological determinants essential for 
protection. The non-glycosylated internal M protein has been implicated in the 
establishment or maintenance of persistent virus infections. The role of the 
other internal components of the paramyxoviruses (NP, P, L) in the 
pathogenesis and immunological response is poorly understood. 
The attachment of paramyxoviruses to the cell surface is mediated by the 
HN glycoprotein. Host cell receptors for the paramyxoviruses have not been 
characterized In detail but viruses with neuraminidase activity (the genus 
paramyxovirus) probably use neuraminic acid containing cell surface 
glycoproteins as receptors, whereas viruses lacking this activity (the 
morbilliviruses and the pneumoviruses) may use some other surface molecules. 
The receptors are pancellular, as most paramyxoviruses can infect epithelial, 
lymphoid monocytic, brain and lung cells, but need to be characterized In more 
detail. In terms of pathogenesis, the adsorption of paramyxoviruses to the cell 
membrane also alters the membrane fluidity and permeability (Kohn, 1979). 
The penetration of paramyxoviruses into the host cell and the cell to cell 
spread of the virus depend on the fusion activity of the F protein. The fusion 
capacity has been located in the hydrophobic F, NHj-terminus (Richardson 
et al., 1980; Richardson et al., 1986; Portner et al., 1987). The F protein is also 
responsible for multinucleated cell formation both in vivo and in vitro. 
The difference in paramyxovirus replication in different cell types may be 
seen at levels other than virus attachment or penetration which could relate to 
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viral tropism and hence pathogenesis. A likely difference is the requirement of 
cellular function(s) in RNA replication, which may not be available in all cell 
types. The site of replication is the cytoplasm, but some paramyxoviruses 
require nuclear functions for a full cycle of replication (Pringle, 1977). The exact 
role of the nucleus in the replication of these viruses has not been determined, 
but a nuclear enzymatic function may be necessary for replication, as has been 
shown in orthomyxovirus replication. 
An important determinant in the pathogenesis of paramyxovirus infections 
is the requirement for proteolytic cleavage of the FQ precursor protein to the F, 
and Fg proteins (Scheld and Choppin, 1974). Although the assembly of the 
virion is independent of cleavage, the produced virus particles are not 
infectious. If the infected cell does not have the right type of protease, the 
released virus particles are not infectious, leading to a self-limited infection and 
reduced pathological consequences. Although one is not sure how it occurs in 
paramyxoviruses, there is a correlation between the cleavability of the F protein 
and the pathogenicity of Sendai virus and NOV (Goswami and Russell, 1982; 
Nagai et al., 1976). The cleave-activation site of the virulent NDV strains 
consists of dibasic residues with an intervening glutamine, that is Gly-Lys-Arg-
Qln-Gly-Ser-Arg- (Toyoda et al., 1987). On the other hand, failure to cleave the 
F protein may also be a contributing factor in the establishment of virus 
persistence (Fujinami and Oldstone, 1981). It has been suggested that one 
could use a trypsin resistant mutant of Sendai virus as a non-pathogenic 
17 
vaccine tliat induces a protective immunity against challenge with a virulent 
strain (Tashiro and Homma, 1985). 
Virus infections efficiently disrupt the functions of the infected cells. The 
fate of virus following replication is a key factor in determining the degree of 
pathogenesis. Lytic infection by paramyxoviruses generally leads to rapid 
destruction and death of the host cells. During late stages of infection when a 
large amount of viral envelope protein is inserted into the plasma membrane, 
there is alteration in the membrane fluidity and permeability. Another 
mechanism of cell damage is. the appearance of hydrophobic pores on the 
plasma membrane, which leads to leakage of ions and low molecular weight 
compounds with subsequent loss of cellular functions (Pasternak et al., 1985). 
This effect is mediated by the F protein. 
Cells infected with paramyxoviruses release soluble material that may be 
important in pathogenesis. Viral envelope glycoproteins released from infected 
cells may have pathogenetic significance, particularly In immunopathological 
reactions. On the other hand excess viral proteins may have a toxic effect on 
infected cells, as seen in many other viral infections. 
Inhibition of host cellular RNA synthesis has been described for the 
isolated glycoproteins of mumps virus (Yamada et al., 1984). It has been found 
that certain viral related factors have an influence on the pathogenesis as is the 
case with BPI-3 virus isolates which vary in their ability to produce different 
amount of neuraminidase (Shibuta et al., 1981). BPI-3 viruses (M-YN and SC-
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YN) formed only pinhole plaques or no plaques in the absence of 
neuraminidase. Exogenous neuraminidase enhanced replication of both the 
viruses and reduced syncytial formation by these viruses. 
Virus infections also cause the release of soluble cellular factors, which 
take part in the pathogenesis of diseases. Paramyxoviruses are efficient 
interferon inducers, with Sendai virus being one of the best inducers of human 
leukocyte interferon. The induction is thought to occur during the replication of 
the virion RNA, but it has also been shown that the HN protein and transfected 
cDNA of the Sendai virus nonstructural C gene can induce interferon production 
(Taira et al., 1987). Paramyxoviruses can also induce other molecules of 
biological importance, such as tumor necrosis factor produced by peripheral 
blood leukocytes or mononuclear phagocytes infected with Sendai virus 
(Aderka et al., 1986). 
Aspects of Immunity 
Antigenicity of the Paramyxoviridae 
Characterization and study of the individual viral constituents is 
necessary in order to understand their probable role in the Initiation of infection, 
virus interaction with immune cells and subsequent protection against infection. 
However, the latter two attributes are concerned with the so called 
antigenic/immunogenic components of the virus. The major epitopic 
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determinants of paramyxoviruses are said to be stable and immunization or 
infection provides protection for a fairly long period of time. Our present 
understanding of the antigenic structure of paramyxoviruses has been largely 
derived from monoclonal antibody studies (Orvell and Norrby, 1985). Gene 
technology now offers the possibility to analyze and compare antigenic 
structures of immunologically important proteins at the molecular level due to 
the sequencing of paramyxovirus genes. All viral proteins can function as 
antigens and immunogens, but viral glycoproteins are the most important in the 
antibody response. Although the other paramyxoviral structural components 
are accessible to the immune system, their importance in Immunity is not 
known. The HN protein is the major immunogenic subunit responsible for the 
induction of neutralizing antibodies to the paramyxoviruses. Two to four non-
overlapping, topologically distinct antigenic sites with variable epitopes occur on 
the HN glycoprotein of paramyxoviruses (van Wyke Coelingh et al., 1985; 
Coellngh et al., 1986; Nishikawa et al., 1986; Portner et al., 1987). The 
antigenic sites essential for neutralization on the envelope glycoproteins (HN 
and F) have been defined on the paramyxovirus group. In human and bovine 
PI-3 viruses, HN glycoproteins share two neutralization epitopes in antigenic site 
A, whereas, three neutralizing epitopes are shared on the F glycoproteins 
(Coelingh, 1989; van Wyke Coelingh and Tierney, 1989; Coelingh et al., 1986). 
The two shared epitopes on HN, as well as two of the three shared epitopes on 
F, are completely consen/ed among HPI-3 virus isolates, whereas, the third 
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shared epitope on F is highly conserved (97%). Bovine and human PI-3 viruses 
also exhibit significant conservation of amino acid sequence; homology of the 
NP, P, C, and M proteins varies from 62% to 86%, whereas, homology of the F 
and HN surface glycoproteins is 80% and 77%, respectively (Sakai et al., 1987; 
Suzu et al., 1987). The observation that different monoclonal antibodies against 
the HN protein of NDV have a synergistic neutralizing effect (Russell, 1986) 
endorses the view that more than one site is important for full neutralization 
capacity. 
Most members of the Paramyxoviridae family are monotypic as well as 
cross reactive to a certain degree. Strain variation does occur 
(Sheshberadaran et al., 1983; llonen et al., 1988). The variation may not have 
immunological consequences but may be of biological significance, for example, 
in the establishment of persistent virus infections. One of the suggested 
mechanisms of measles virus persistence in subacute sclerosing 
panencephalitis (SSPE) patients is the lack of a functional M protein (Hall et al., 
1979; Hall and Choppin, 1981). It may be that the rapid accumulation of point 
mutations in different genes during paramyxovirus infections causes different 
replication defects (Baczko et al., 1986) that prevent the assembly of virions and 
lead to persistency. There are reports of antigenic relationships among the 
paramyxoviridae family (Cook et al., 1959; Goswami and Russell, 1982; 
Julkunen, 1984; Ray and Compans, 1986). This antigenic relationship may 
widen the candidacy of individual viruses as vaccines. Ito et al. (1987) divided 
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the genus paramyxovirus into two groups according to antigenic 
Interrelationship by immunopreclpltating radiolabelled polypeptides with specific 
antiserums. Sendai virus and human parainfluenza virus types 1 and 3 belong 
to the first group, and human parainfluenza virus types 2 and 4 , mumps, and 
SV-5 belong to the second group. NDV cross-reacts with the human 
parainfluenza viruses. 
Antigenic relationships have also been reported between different viral 
proteins including glycoproteins as well as nucleoproteins. Among these, the 
nucleoprotein shows the broadest cross-reactivity, and the overall homology 
estimated for nucleoproteins of members of the genus paramyxovirus is around 
70 percent. The viral glycoproteins are also cross-reactive, but the M protein is 
antigenically most specific. 
Antibody response 
The antibody responseTin natural paramyxovirus infections is directed 
against both the surface and internal components of the virion (Kasel et al., 
1984; Ward et al., 1983; Hankins and Black, 1986). However, the protective 
antibody is directed against the HN and F proteins of the virion. Earlier, human 
vaccination studies suggested that in vitro neutralization of the virion requires an 
immune response against the HN protein, but In vivo protection requires 
response to the F protein as well. Further evidence has confirmed that 
antibodies against both these molecules are needed for full protection against 
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HPI-3 and measles viruses in liumans and distemper virus in dogs (Spriggs 
et ai., 1987; Norrby et al., 1975, 1986). 
The importance of antibodies in protection against severe infection has 
been confirmed in animal experiments in which antibodies were injected into 
experimental animals followed by challenge with Infectious virus. Lethal 
infection by NDV was prevented by passive administration of antibodies against 
the whole virion (Umino et a!., 1987). Passively administered neutralizing 
antibodies to either HN protein or the F protein gave only a partial protection 
against a lethal infection, but simultaneous administration of these two 
antibodies increased the protection. 
Human RSV convalescent serum was shown to protect cotton rats from 
infection (Prince et al., 1985). The protection rate, however, was influenced by 
the route of serum administration. The effect was 180 times greater when 
administered topically than by parental administration in reducing virus titer In 
pulmonary tissues of cotton rats (Prince et al., 1987). 
The major neutralization site of pneumoviruses is on the F protein (Walsh 
et al., 1985). This is supported by the in vitro and In vivo observations that the 
antibody response in acute primary RSV infection is mainly directed against F 
protein (Vainionpaa et al., 1985) and titers of anti-RSV antibodies (anti-F 
antibodies) correlate well with the neutralizing activity of human sera (Faden 
et al., 1984). 
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Neutralization by monoclonal antibodies in vitro and their protective ability 
in vivo have also been studied. Some monoclonal antibodies specific for the 
HN or F components have neutralizing or protective activity (Giraudon and Wild, 
1985; Love et al., 1986; Rydbeck et al., 1988), confirming that the neutralizing 
and protective epitopes reside on these molecules. However, a number of 
antibodies specific for these components do not alter their biological activities, 
in accord with the notion that the protective immunity is against only a small 
region of the glycoprotein. 
The neutralization of mumps virus requires antibodies against HN rather 
than F protein. No protection was observed when monoclonal antibodies to the 
F protein of mumps virus were injected into an experimental animal with mumps 
virus meningoencephalitis, whereas antibodies to HN proteins provided 
protection against the infection (Wolinsky et al., 1985). It was further shown 
that a topographically restricted region of the HN polypeptide was critical for 
protection. For complete protection, antibodies against both HN and F 
glycoproteins seem to be needed to prevent paramyxovirus infection (Love 
et al., 1986; Rydbeck et al., 1988). 
The importance of the surface components in protection has been 
studied by injecting purified virus glycoproteins or recombinant vectors 
expressing HPI-3 virus or RSV glycoproteins. Immunity elicited in cotton rats 
immunized with both glycoproteins provided complete pulmonary resistance 
against challenge with infectious virus (Spriggs et al., 1987; Walsh et al., 1987). 
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The F protein of RSV in a recombinant vaccinia vector expressing both 
glycosylated F, and Fa was used to vaccinate mice (Wertz et al., 1987). The 
immunization inhibited a productive lung infection after intranasal challenge with 
a virulent RSV. Human RSV G protein expressed by a recombinant vaccinia 
virus gave complete protection in mice against live virus challenge (Stott et al., 
1986). 
Vaccinia virus recombinants with SV-5 HN and F protein inserts have 
also been studied for their protection inducing capacity In rabbits and hamsters 
(Paterson et al., 1987). Both recombinants induced high levels of neutralizing 
antibodies, but HN recombinants gave better protection against the challenge. 
T-cell response 
The cellular immune response against paramyxovirus infection is crucial 
for protection. Supporting evidence came from the clinical observation of 
severe paramyxovirus Infections in patients with a T-cell deficiency. Children 
with compromised immune functions and the patients with the acquired immune 
deficiency syndrome (AIDS) are in danger of developing complicated or fatal 
paramyxovirus infections (Hall et al., 1986). 
The specificity and nature of the protective T cells in paramyxovirus 
infections has not been demonstrated. Cytotoxic T cells have been shown to 
develop during human paramyxovirus infections and memory cells can be 
demonstrated by in vitro stimulation of peripheral blood lymphocytes (Casali 
25 
and Oldstone, 1982). Bangham and McMichael (1986) observed that human 
cytotoxic T cells recognize B-cell lines persistently infected with RSV. In another 
experiment, monoclonal antibodies were complexed to the solid matrices to 
purify virus proteins from SV-5 infected tissue culture cells (Randall and Young, 
1988). The resulting solid matrix-antibody-antigen (SMAA) complexes were 
used as immunogens. These complexes successfully induced specific humoral 
and cytotoxic T cell responses. Analysis of the cytotoxic T cell response of 
immunized animals indicated that both surface and internal SV-5 structural 
proteins can act as target antigens. In continuation of this study, Randall et al. 
(1988) found that prior immunization of mice with SMAA complexes containing 
either surface or internal virus structural proteins reduced the amount of virus 
replication within infected lungs following challenge. The greatest degree of 
protection was observed when nucleoprotein or matrix protein was used to 
immunize the mice. There was no correlation between the degree of protection 
observed and the level of neutralizing antibody present in immunized animals; 
no neutralizing antibody was detected in mice immunized with internal virus 
proteins. It was concluded that the protection observed in immunized mice was 
through the induction of cytotoxic T cells. 
Cytotoxic T cells can be found in the spleen of mice infected intranasally 
with RSV (Bangham et al., 1985). Cotton rats, similarly, developed cytotoxic T 
cells following intranasal RSV infection but not after subcutaneous infection or 
immunization with virus antigens (Kumagai et al., 1985). Cytotoxic cells 
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appeared 4 days postinfection in tine lungs and 7 days postinfection in the 
spleen. If these cells are important in the elimination of RSV, the observation 
has important implications for vaccination. 
The individual viral constitutive proteins variably induce cytotoxic T-
lymphocytes. The HN and F glycoproteins of Sendai virus inserted on 
liposomes Induced cytotoxic T-cell response. The cells reacted at low level 
when individual glycoproteins were used but when both glycoproteins were 
inserted Into liposomes, the cytotoxic activity was as strong as with Infected 
cells (Al-Ahdal et al., 1985). It has recently been shown in a vaccinia virus 
expression system that both mouse and human cytotoxic T cells specific to RSV 
recognize the viral nucleoprotein but not the major glycoprotein (Bangham 
et al., 1986). The RSV F protein can also be an important target in BALB/c 
mice but no information on such specificity is available in the human system 
(Pemberton et al., 1987). However it was demonstrated that immunization of 
individuals with both the internal and surface polypeptides of measles virus can 
stimulate peripheral blood lymphcytes (llonen et al., 1980). The polypeptide 
specificity of the blastogenic assay has been studied with T cell lines and clones 
established from the peripheral blood of a patient with multiple sclerosis (Richert 
et al., 1986). Of 11 clones, three were specific for the F protein, one for the HN 
protein and the rest showed specificities to more than one polypeptide, 
including the Internal proteins P, NP and M. The results suggest that all the 
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viral polypeptides may have some importance in the cellular reactions at the site 
of infection. 
Although the G glycoproteins of RSV subgroup A and B differ 
substantially from each other (Johnson et al., 1987), polyclonal RSV specific 
cytotoxic T cells recognized syngeneic target cells Infected with every human 
RSV strain tested, (Bangham and Askonas, 1986). The results suggest that the 
epitope recognized by the cytotoxic T cells is not in the variable region of the G 
protein. With influenza virus, the T-cell cross-reactivity among strains is mainly 
against thé nucleoprotein antigen. However, such cytotoxic T-cell reactivity was 
not seen between various strains of mumps, Sendai and Newcastle disease 
viruses in vitro (Hosaka et al., 1986). 
It is too early to evaluate the. significance of different T cells and their 
specificities from the protection point of view. Recent evidence however, 
indicates that specific cytotoxic T cells are found in the lungs of mice infected 
with RSV. It was further shown that there Is a close relationship between 
appearance of these cells in the circulation and clearance of virus that persisted 
in the lungs of nude mice (Taylor et al., 1985). Whether cytotoxic T cells play a 
similar role in other paramyxovirus infections is not yet known. Further, both 
cytotoxic and helper T cells seem to be necessary for the full protection against 
a lethal Sendai virus infection in mice (Kast et al., 1986). 
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Vaccines 
The most efficient and economical way of controlling the viral infections 
is through immunoprophylaxis. A wide variety of vaccines are used to prevent 
PI-3 virus infection. These are either killed or live vaccines which are available 
currently. The efficacy of these in some cases is doubtful not only because of 
the Inherited disadvantages of both killed and live vaccines but also due to the 
poor immunological response in some instances, ubiquitous nature of the virus, 
limited antigenic studies and presence of maternal antibodies at the time of 
vaccination. The study regarding PI-3 virus vaccines started very early to 
prevent human parainfluenza virus infection. Inactivated parainfluenza virus 
vaccines prepared in embryonated eggs or primary monkey kidney cell culture 
for types 1, 2 and 3 have been shown to be antigenic in children as indicated 
by the development of serum HI and neutralizing antibodies. Unfortunately, 
parenteral administration of these vaccines failed to provide resistance against 
parainfluenza virus disease (Chin et al., 1969; Fulginiti et al., 1969). This is not 
surprising in view of the importance of local secretory IgA antibody in resistance 
and the relative ineffectiveness of inactivated vaccines in stimulating this 
response. In addition, selective Inactivation of F glycoprotein by formalin may 
have also contributed to the lack of efficacy of inactivated vaccine. 
In the past few years, several approaches to the development of 
parainfluenza virus vaccines have shown some promise. For example, the gene 
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for the HN of HPI-3 virus has been inserted into a baculovirus expression vector 
under the control of the baculovirus polyhedrin promoter (Coelingh et al., 1987). 
Immunization of cotton rats with a lysate of insect ceils containing HN 
expressed by the recombinant Induced complete resistance to infection by 
HPI-3 virus in the lower respiratory tract (Coelingh et al., 1987). 
Another approach to PI virus Immunoprophylaxis involves the use of a 
stable, attenuated live vaccine virus to construct viable recombinants that 
express PI-3 virus protective antigens. To date, the greatest success has been 
achieved using vaccinia virus as a recombinant vector. Vaccinia virus 
recombinants containing the gene for HPI-3 virus F or HN proteins express the 
appropriate viral glycoprotein in a form that appears to be authentic both 
biochemically and immunologically (Spriggs et al., 1987). Infection of cotton 
rats with either vaccinia recombinant induced a high level of HPI-3 virus specific 
serum neutralizing antibodies, and immunized animals developed significant 
resistance to challenge with HPI-3 virus (Spriggs et al., 1987). This confirms the 
previous observations that each of the glycoproteins is a major protective 
antigen, although in vivo, HN protein appears to play a greater role in protective 
immunity. Infection of patas monkeys with vaccinia-HPI-3 virus HN protein and 
vaccinia-HPI-3 virus F protein also induced a high level of serum neutralizing 
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antibodies, and immunized animals exhibited significant resistance to HPI-3 virus 
challenge in both the upper and lower respiratory tract (Spriggs et al., 1988). 
Two recombinant vaccinia viruses were constructed expressing F and HN 
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polypeptides from SV-5. Infection of rabbits and hamsters with recombinant 
viruses elicited an antibody response to either F or HN proteins and were well 
protected from challenge when infected with live homologous virus (Peterson 
et al., 1987). These obsen/ations suggest that vaccine strategies that involve 
live, attenuated, recombinant viruses represent a feasible approach to 
immunization against important respiratory paramyxoviruses such as HPI-3. 
Another approach to HPI-3 virus Immunoprophylaxis Involves the oldest 
successful strategy for development of a live virus vaccine. This strategy, first 
used by Jenner, involves the use of a virus strain of animal origin to immunize 
humans against a human virus that Is antigenically closely related to HPI-3 virus 
(Abinanti et al., 1961). 
Although the BPI-3 virus is distinct from HPI-3 virus, it is capable of 
inducing significant resistance to HPI-3 virus in cotton rats (Coellngh et al., 
1988). For this reason, BPI-3 virus was evaluated further in primates to 
determine its potential as a live virus vaccine for prevention of HPI-3 virus 
disease. Infection of squirrel monkeys with BPI-3 virus Induced a moderate 
immune response to HPI-3 virus, and these animals also exhibited significant 
resistance in their lower respiratory tract to subsequent challenge with HPI-3 
virus (Coellngh et al., 1988). Evidence for attenuation of BPI-3 virus for 
primates was also obsen/ed in rhesus monkeys and chimpanzees (Coelingh 
et al., 1988). Although BPI-3 virus strains were restricted in replication in rhesus 
monkeys, these viruses grew well enough to induce a neutralizing antibody 
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response that should, based upon previous experience, provide resistance to 
HPI-3 virus infection. 
Cold adapted mutants of HPI-3 virus are also being evaluated for their 
usefulness in immunoprophylaxis of respiratory tract disease (Belshe and 
HIssom, 1982; Crookshanks and Belshe, 1984; Crookshanks-Newman and 
Belshe, 1986). Several of these mutants represent promising vaccine 
candidates because (i) their cold adaptation, temperature sensitivity, and small 
plaque phenotypes are stable after replication in cell culture, (ii) their replication 
is restricted both in the upper and lower respiratory tract of hamsters, and (iii) 
they induce significant resistance (in hamsters) to subsequent challenge with 
wild type HPI-3 virus. 
A novel approach to the development of live parainfluenza virus vaccines 
has emerged from the study of Sendai virus mutants selected for an alteration 
in their cleavage site on the F glycoprotein (Hsu et al., 1989; Tashiro and 
Homma, 1985). Cleavage, required for activation of infectivity, is thought to be 
effected by a cellular trypsin-like protease (Gething et al., 1978; Hsu et al., 1987; 
Scheid and Choppin, 1976). Cell cultures that are deficient in this protease 
activity produce Sendai virus bearing uncleaved F glycoprotein, but treatment of 
such non-infectious virus with trypsin cleaves F protein and activates infectivity. 
However, if non-infectious virus is treated with chymotrypsin or elastase, 
spontaneous cleavage mutants can be selected which are resistant to trypsin 
but susceptible to cleavage by the selecting enzyme (Ito et al., 1987; Scheid 
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and Choppin, 1976; Tashiro and Homma, 1985). Mutants that have been 
cleaved by chymotrypsin or elastase, undergo only a single cycle of abortive 
Infection in mice because the virus that Is produced is resistant to cleavage by 
cellular trypsin-like protease (Hsu et al., 1989; Tashiro and Homma, 1985). 
Nonetheless, intranasal installation of a moderate amount of virus (10 pfu) 
induced serum antibodies and significant resistant to subsequent challenge with 
wild type virus (Hsu et al., 1989; Tashiro and Homma, 1985). 
The efficacy of the glycoprotein preparation as a subunit vaccine 
(envelope glycoproteins of HPI-3 virus reconstituted into lipid vesicles) when 
administered to hamsters intranasally or subcutaneously was compared. 
Animals receiving four intranasal immunizations with 5 ug of the glycoprotein 
preparation were completely resistant to challenge infection. Only partial 
protection, however, was observed in animals immunized subcutaneously with 
the same dose of antigen. The difference was due to the local glycoprotein-
specific IgA response in intranasally immunized animals. In another experiment 
Rydbeck et al. (1988) observed that a MAb to the Sendai virus HN protein 
conferred protection against HPI-3 virus infection in hamsters. 
Maternal Immunity 
Newborn animals acquire maternal immunity through ingestion of 
colostrum in bovine and through the placenta in primates. The level of 
antibodies transferred depends upon the immune status of the dam. These 
antibodies can prevent local as well as systemic infections. Most adult animals 
have antibodies against PI-3 virus. These animals are protected against PI-3 
virus infection for the rest of their lives. In sheep and cattle, maternal antibodies 
are transferred through colostrum after birth. The level of antibodies decreases 
and almost disappear when the young animal is between 4 to 6 month of age 
(Bogel and Liebelt, 1963; Dawson, 1966). There are reports that colostrally 
acquired maternal virus-neutralizing antibodies against PI-3 virus in calves may 
also appear in the nasal secretion (McKercher, 1972). Results of an experiment 
conducted on young colostrum-fed lambs indicated that maternal immunity 
alone can prevent infection with PI-3 virus (Smith et al., 1975). In subsequent 
experiments, it was further observed that colostral IgG antibodies can pass into 
the nasal and lachrymal secretions of newborn colostrum-fed lamb. Both IgG, 
and IgGa were transferred at approximately same rate from plasma to nasal or 
lachrymal secretions of newborn and adult sheep. 
It is generally assumed that colostrally acquired maternal antibodies (if 
present in sufficient amount) can protect the young animal against PI-3 virus 
infection because these antibodies can neutralize the virus after natural infection 
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(Bogel and Liebelt, 1963). However, factors other than serum antibodies seem 
to be important in resistance of an animal against PI-3 virus infection and these 
factors may not be reflected by the level of antibody in the serum (Frank and 
Marshall, 1971; Marshall and Frank, 1971). 
The exposure of colostrum-deprived and coiostraliy-acquired maternal 
immunity to aerosol PI-3 virus resulted in signs of infection, leukopenia and 
shedding of virus in nasal secretions (Marshall and Frank, 1975). However, 
infection was not as severe in calves with coiostraliy-acquired maternal immunity 
as it was in colostrum-deprived calves which did not have antibodies against 
PI-3 virus before exposure. All calves responded immunologically to PI-3 virus 
but the level of antibody in serum and nasal secretions at day 30 after viral 
exposure was lower in calves with coiostraliy-acquired maternal Immunity than 
in colostrum deprived calves; serum antibody response in the former group was 
primarily indicated by an anamnestic response after challenge exposure. Serum 
and nasal secretion antibodies increased in all calves after challenge with PI-3 
virus, but antibody titers were generally lower for calves that had colostrum-
acquired maternal antibodies. 
Maternal antibodies can prevent infection in young animals but at the 
same time they can neutralize live virus present in a vaccine. Bogel and Liebelt, 
(1963) reported that antibodies can interfere with the development of active 
immunity after live PI-3 virus vaccination. Later on, Schell et al. (1972) could not 
detect an increase in serum antibody level (in the presence of colostrally 
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acquired immunity), wlien attenuated virus was administered by simultaneous 
intramuscular and intranasal inoculations and when a live virus vaccine was 
given by intramuscular route. The impairment can also occur in the generation 
of cytotoxic activity, as shown by a passive transfer of maternal antibodies in 
the mouse model of RSV (Bangham et al., 1985). 
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PART I. IMMUNE RECOGNITION OF PARAMYXOVIRUS POLYPEPTIDES 
BY LAMBS 
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ABSTRACT 
Parainf!uenza-3 (PI-3) virus is a significant patiiogen in tlie respiratory tract 
of lambs. The objective of present study was to determine the potential role of a 
heterotypic paramyxovirus vaccine for immunization of lambs against PI-3 virus 
infection. 
Polyclonal antiserums were produced in lambs against bovine PI-3 (BPI-3) 
virus, human PI-3 (HPI-3) virus, Sendai virus and simian virus-5 (SV-5). Humoral 
response and specificity of the antiserums against the proteins of all the viruses 
was determined by the use of hemagglutination inhibition (HI) test, enzyme linked 
immunosorbent assay (ELISA), Western immunoblot assay (WIA), and 
radioimmunoprecipitation assay (RIPA). 
The results of present studies demonstrated that BPI-3 and HPI-3 viruses 
are closely related antigenically. These viruses share epitopes on their 
phosphoprotein, hemagglutinin/neuraminidase protein, nucleoprotein, fusion 
protein, and matrix protein. However, differential responses in HI tests, and ELISAs 
indicated that there are also some antigenic variations. Sendai virus was also 
found to share some epitopes with the PI-3 viruses. Antigenic crossreactivity of 
SV-5 antiserum was limited to the nucleoprotein of other viruses. 
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INTRODUCTION 
Parainfluenza viruses belong to the genus paramyxovirus included in the 
family Paramyxoviridae. Other viruses in this genus which are primary pathogens 
for animals are Sendai, simian virus-5 (SV-5), and Newcastle disease virus (NOV). 
Among the parainfluenza (PI) viruses, bovine PI-3 (BPI-3) and human PI-3 (HPI-3) 
viruses cause infections of the upper respiratory tract of animals and humans 
respectively (Reisinger et al., 1959; Glezen et al., 1984). The clinical disease 
caused by BPI-3 virus in animals varies in severity and the most important 
consequence is the bacterial pneumonia that may ensue. Serological (Davies and 
Humphreys, 1977; Jones et al., 1979) and experimental (Sharp et al., 1978) 
evidence indicates that PI-3 virus may be an important factor in initiating 
pneumonia in cattle and sheep. The virus suppresses resistance mechanisms in 
the respiratory tract and thereby predisposes to infection with bacterial agents 
(Davies et al., 1986). Control of PI-3 virus infection may be one of the most 
important contributors to the prevention of pneumonia. A variety of different 
vaccines are utilized to prevent this infection In domestic animals. Antigens 
associated with these PI viruses have received extensive study, but knowledge of 
their interrelationships with other members of the genus is limited. 
Bovine PI-3 virus consists of at least six structural proteins including the 
large (L), phospho (P), hemagglutinin-neuraminidase (HN), nucleocapsid (NP), 
fusion (F), and matrix (IVI) proteins (Shibuta et al., 1979; Morein et al., 1983; 
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Panigrahi et al., 1987). A cellular actin (A) protein, associated with many enveloped 
viruses, has also been reported as a seventh protein in BPI-3 virus (Panigrahi et al., 
1987). Some of these proteins are important as protective antigens in immunity 
against the infection. Morein et al. (1987) reported that protection against PI-3 
virus infection in lambs was mediated by an immune response to HN and F surface 
glycoproteins. Immunity to both of these envelope proteins seems to be important 
in diseases caused by other paramyxoviruses (Norrby et al., 1975). Monoclonal 
antibodies (MAbs) directed against these proteins have been shown to prevent 
infection in animals (Ray and Compans, 1986; Ray et al., 1988). 
The structural proteins of H PI-3 and BPI-3 viruses are similar in number and 
size to each other and to those of other members of the Paramyxoviridae family 
(Guskey and Bergtrom, 1981; Jambou et al., 1985; Sanchez and Benerjee, 1985; 
Shibuta et al., 1979; Storey et al., 1984). They also possess similar biologic 
properties such as hemagglutination, neuraminidase activity and membrane fusion. 
Antigenically, these two viruses can be differentiated but they do share some 
neutralizing epitopes (Muchmore et al., 1981; Glezen et al., 1984; Coelingh et al., 
1986). Evidence of shared epitopes has been provided by a number of different 
studies. Antigenic analysis using MAbs in hemagglutination inhibition (HI) and 
plaque neutralization tests indicated that the HN proteins of HPI-3 and BPI-3 
viruses appear to be antigenically dissimilar although they share at least one 
common epitope (Ray and Compans, 1986). Also, Coelingh et al. (1986) reported 
three conserved antigenic sites associated with human and bovine strains, one of 
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which is defined by neutraiizing and hemaggiutinating activity. Coeiingh et al. 
(1987) observed that infection of cotton rats with BPI-3 virus induced resistance to 
Infection with HPI-3 virus. Non-human primates administered live BPI-3 virus also 
resisted a challenge with HPI-3 virus (Coeiingh et al., 1988). It was observed using 
radioimmunoprecipitation that these two viruses have crossreactivity between HN, 
F, NP, and M proteins (Rydbeck et al., 1987; Klippmark et al., 1990). 
Observations on the antigenic composition of BPI-3 and HPI-3 viruses, 
together with the crossprotection studies, indicate some potential for the use of 
these viruses for heterotypic immunization. This approach has been used 
successfully by the application of measles virus for immunization of puppies against 
canine distemper virus infection (Appel et al., 1984). The potential application of a 
related paramyxovirus for immunization of lambs against PI-3 virus led to the 
present experimentation. Paramyxoviruses including BPI-3, HPI-3, Sendai and 
SV-5 were selected for a concerted study of their antigenic relationships. 
Antiserums were produced in lambs against each of these viruses. These serums 
were utilized In HI tests, enzyme linked immunosorbent assays (ELISAs), Western 
immunoblot assays (WIAs), and radioimmunoprecipitation assays (RIPAs) to 
determine serological crossreactivity and for the identification of shared polypeptide 
specificities among these paramyxoviruses. 
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MATERIALS AND METHODS 
Viruses, Cells, and Medium 
The viruses used in the experiment and their source 
were as foilows: 
1. Bovine PI-3 virus - - American Tissue Culture Collection (ATCC) # VR-281. 
2. Human PI-3 virus - - courtesy Dr. Robert C. Chanock, National Institutes of 
Health, Bethesda, MD. 
3. Sendai virus - - ATCC # VR-105. 
4. Simian virus 5 - - courtesy Dr. Max Appel, Cornell University, Ithaca, NY. 
A primary cell line of ovine fetal turbinate (OFT) cells (courtesy Dr. Howard 
Lehmkuhl, National Animal Disease Center (NADC), Ames, lA) were used, unless 
otherwise mentioned, to propagate all four viruses. Growth medium used was 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% ovine serum 
(NADC, Ames, lA) and 1% L-glutamine ( GIBCO Laboratories, Grand Island, NY). 
Gentamicin sulfate (Schering Corporation, Kenilworth, NJ) was added at the rate of 
5 mg/100 ml of medium. 
Propagation of Viruses 
Primary virus cuiture 
Madin-Darby bovine kidney (MDBK) cells were used to prepare primary 
cultures of each virus except Sendai virus which was propagated as described 
later. MDBK cells were grown in polystyrene 150 cm^ flasks (Corning Glass Works, 
Corning, NY) containing 30 ml DMEM supplemented with 10% fetal calf serum 
(PCS) and 5 mg/100 ml gentamicin sulfate. A confluent cell monolayer was 
infected with each virus at a multiplicity of infection (MOI) of 5 plaque forming units 
(PFU) per cell and the virus was allowed to adsorb for 60-90 minutes at 37°C in an 
incubator with 5% COg. After viral adsorption, the inoculum was removed and 
replaced with 30 ml of DMEM containing 1% PCS and 5 mg/100 ml of gentamicin 
sulfate. When cytopathic effect was evident in about 80% of the monolayer (3-5 
days), the flasks were frozen at -70°C. The flasks were thawed at room 
temperature, the suspensions were aliquoted and stored at -70°C. 
Cultivation of Sendai virus 
A stock preparation of Sendai virus was diluted (1:512, 1 hemagglutination 
(HA) titer/ml) in phosphate buffered saline (PBS, pH 7.2, 14mM potassium 
phosphate monobasic, 26mM potassium chloride, 8mM sodium phosphate dibasic, 
Sigma Chemical Company, St. Louis, MO). Ten specific pathogen free 
embryonated eggs (9 day old) were used to propagate Sendai virus. The eggs 
43 
were candled to observe the viability of the embryo. An area of the chorioallantoic 
membrane that was free of large blood vessels was marked with lead pencil. The 
marked area of each egg was swabbed with 70% alcohol. A small hole was made 
through the shell at the upper extremity over the air cell using 18 guage 1" needle. 
Eggs were inoculated with 0.1 ml of the virus suspension with a one ml tuberculin 
syringe fitted with 27 guage 1 /2" needle. The holes were closed with liquid wax 
and eggs were incubated at 37°C in a humidified incubator. Eggs were candled 
daily to observe for the viability of the embryos. After 72 hours (h), the eggs were 
placed in a refrigerator at 4°C for 3 h. 
To collect the allanto-amniotic fluid, the shell of the egg was swabbed with 
70% alcohol. The shell over the air cell was cracked and removed using sterile 
forceps and scissors as were the allanto-amniotic membranes. Allanto-amniotic 
fluid (10-15 ml) was collected with a sterile 10 ml glass pipette. Fluid from each 
egg was pooled in plastic tubes and centrifuged at 300 g for 30 minutes. 
Supernatant fluid was collected and the sterility was checked by culturing on blood 
agar plates incubated at 37°C for 48 h. Presence of virus was determined by a 
hemagglutination (HA) test. The virus preparation was aliquoted and stored at 
-70°C. 
Propagation of viruses for vaccine preparation 
Ovine fetal turbinate cells were grown in polystyrene flasks (150 cm^, 
Corning) containing 30 ml of DMEM. When a monolayer of cells had formed, the 
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medium was replaced with 5 ml of 0.2% trypsin (Difco Laboratories, Detroit, Ml) 
and incubated at 37°C for 3-5 minutes. Trypsinized cells from three flasks were 
transferred to a roller bottle (850 cm^, Corning) containing 70 ml of DM EM. The 
roller bottles were incubated at 37°C and rolled at a speed of 16 revolutions/h. 
After 24 h when the cell monolayer was complete, the medium was removed and 
the cells were infected at a MOI of 1-2 PFU/cell with the primary virus suspension. 
Following virus adsorption in the roller apparatus for 60-90 minutes the virus 
suspension was removed from all roller bottles, replaced with 70 ml DMEM 
(supplemented with 1% ovine serum and 5 mg/100 ml Gentamicin sulfate) and 
incubated at 37°C. When cytopathic effects were evident in 90% of the cell sheet, 
each virus preparation was subjected to three freeze-thaw cycles at -70°C. The 
virus suspension was centrifuged at 3000 x g to sediment cell debris. The cell free 
supernatant of each virus was aliquoted and stored at -70°C. 
Virus Purification 
Virions present in each cell free suspension (about 800 ml) were sedimented 
by centrifugation for 2 h at 100,000 g in a Sorvall T 647.5 rotor. Pelleted virions 
were resuspended in 3 ml of PBS. A discontinuous sucrose gradient consisting of 
60% (4 ml), 30% (4 ml), and 15% (3 ml) of sucrose in PBS was prepared in a 
polyallomer centrifuge tube (38.5 ml). Resuspended virus was layered onto 
individual sucrose gradients and centrifuged for 3 h at 100,000 g in a Beckman 
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SW 27 rotor. A band present at the interface of the 30 and 60% sucrose layers 
was collected using a sterile Pasteur pipette. This material was dialyzed for 24 h at 
4°C against four changes of PBS using 12-14000 MW cutoff dialysis tubing (Fisher 
Scientific, Pittsburg, PA). The dialyzed preparations were centrifuged for 2 h at 
100,000 g in a Beckman SW 27 rotor. The pellets were resuspended in 8-10 ml of 
PBS and stored at -70 °C. Presence of virus in the preparations was confirmed 
with an HA test. 
Preparation of Vaccines 
The protein content of each purified virus suspension was determined with 
the bicinchoninic acid (BCA) protein assay procedure (Pierce Laboratories, 
Rockford, IL). Each virus suspension was adjusted to a protein concentration of 2 
mg/ml by the addition of PBS. Gentamicin sulfate was added at a concentration of 
5 mg/100 ml to these preparations and the mixture incubated overnight at 4°C. 
Each virus suspension (1.5 ml) was emulsified in an equal volume of Freund's 
complete adjuvant (Sigma Chemical Company, St. Louis, MO) by use of a 
homogenizer (VirTis "23" homogenizer, VIrTIs Company, Inc. Gardiner, NY). The 
vaccines were prepared shortly before each application and held in a styrofoam 
box containing an ice packet until administered. Booster preparations were 
prepared in the same manner except that Freund's incomplete adjuvant was used. 
Production of Hyperimmune Serums 
Lambs sero-negatlve for all paramyxoviruses utilized in the study were 
immunized for the production of hyperimmune serums, two lambs with each virus. 
Each sheep was administered 1 ml of a respective virus vaccine (containing 1 mg 
of virus protein) subcutaneously at two different sites (0.5 ml behind each ear). A 
booster injection was given on day 42 following primary immunization. Blood 
samples (50 ml each) were collected from the jugular vein of each sheep at 0, 3, 4, 
6, 8, and 9 weeks following primary immunization. Blood samples were allowed to 
clot and held at room temperature over-night. The samples were centrifuged for 30 
minutes at 2000 g for serum separation after which the serum was removed and 
stored at -20°C. 
Hemagglutination Inhibition Test 
Standardization of sheep red blood cells 
Twenty ml of blood was collected from a healthy sheep into a sterile glass 
tube containing an equal volume of Alsever's solution (110mM glucose, 70mM 
NaCI, 20mM trisodium citrate, 3mM citric acid). The diluted blood was centrifuged 
at 500 g for 20 minutes. The supernatant was discarded and the packed cells 
were resuspended to the original volume in normal saline solution. The cell 
suspension was again centrifuged as described before. The packed cells were 
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washed 3 times in this manner and resuspended at an appropriate concentration in 
PBS. This suspension, when diluted (1:20) In 0.1% sodium carbonate solution, 
gave an optical transmittance of 85% at a wavelength of 540 on a 
spectrophotometer (Spectronic 20, Bausch & Lomb). 
Hemagglutination titer of bovine PI-3 virus 
Cells and bovine PI-3 (BPI-3) virus were grown as described for the 
preparation of ELISA antigens. The hemagglutination (HA) titer of BPI-3 virus for 
use in hemagglutination inhibition (HI) tests was determined. Two-fold serial 
dilutions of virus (50 //I) were made in PBS (1:2 to 1:4096) in a 96 well round 
bottom microtiter plate (Costar, Cambridge, MA). A standardized suspension of 
sheep red blood cells (SRBCs) was added (50 //I) to each virus dilution. The plate 
was incubated at room temperature for 3 h. The HA titer of virus was recorded as 
the last dilution showing agglutination. For use in the HI test, the virus suspension 
was diluted in PBS to a concentration of 4 HA units/50 //I. 
Hemagglutination inhibition test procedure 
Hemagglutination inhibition tests were carried-out in round bottom 96 well 
microtiter plates (Costar). PBS (50 /ul) was added to each well of the plate. Serum 
samples (50 //I), including negative and positive controls, were added to the first 
well of each row. Two-fold-dilutions of each serum were made by mixing the 
suspension thoroughly (10-15 times using a multichannel micropipetter) and 
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transferring 50 //I of this suspension into subsequent wells. Fifty //I of the diluted 
serum was discarded from the last well. Bovine PI-3 virus (4 HA units) was added 
(50 //I) to each well and the plates were incubated at room temperature for 30 
minutes. After this period, SRBCs (50 //I) were added to each well. Plates were 
Incubated at room temperature for about 3 h. The HI titer of each serum was 
recorded as the last serum dilution inhibiting agglutination. 
Enzyme-Linked Immunosorbent Assay (ELISA) 
Preparation of ELISA antigens 
ELISA antigens were prepared (for all four viruses) according to the method 
described by Florent and De Marneffe, (1986) with modification. Madin-Darby 
bovine kidney cells were grown in 75 cm^ flasks (Costar) containing 20 ml DMEM 
as described previosly. Confluent cell monolayers were infected at a MOI of 1-2 
PFU/cell and the virus was allowed to adsorb for 60-90 minutes at 37°C in an 
incubator with 5% COg. After adsorption, the inoculum was removed and replaced 
with 20 ml of serum free DMEM containing gentamicin sulfate (5 mg/100 ml). 
When cytopathic effect was evident in about 80% of the monolayer (3-5 days), the 
flasks were frozen at -70 °C. For antigen preparation, the flasks were thawed at 
room temperature, the suspensions were harvested and centrifuged at 100,000 g in 
a Beckman SW 27 rotor for 2 h at 4°C. The resulting pellets were resuspended at 
a 40x concentration in PBS and placed on ice. Each suspension was pulse 
sonicated at 50% duty cycle for 30 seconds (Sonifier cell disrupter 350, Branson 
Sonic Power Company, Danbury, CT) and centrifuged at 2000 g for 20 minutes to 
sediment debris. The supernatants were removed and stored at -70 °C. A control 
ELISA antigen was prepared in a similar manner from mock-infected MDBK cells. 
ELISA procedure 
Both viral and control antigens were diluted in antigen- coating buffer 
containing 15mM sodium carbonate and 36mM sodium bicarbonate (pH 9.6). One 
hundred p\ of each antigen preparation (containing 1 jjg protein) was added to 
individual wells of polystyrene microtiter plates (Immulon I microplates, Dynatech 
Laboratories Inc., Alexandria, VA) and incubated at 37°C for 2 h. Unadsorbed 
antigen was removed by washing all wells three times with ELISA wash buffer (pH 
7.2, 0.13M sodium chloride, 150mM potassium dihydrogen phosphate, 320mM 
sodium hydrogen phosphate 12H2O, 270mM potassium chloride and .05% Tween 
20). One hundred fj\ of ammonium chloride (0.1M) was added to each well to 
block unreacted sites. Plates were incubated for 30 minutes at 37°C. Plates were 
again washed three times with ELISA wash buffer. Two-fold dilutions (1:100 to 
1:800) of each serum were made in PBS containing 0.05% Tween 80 and 1% horse 
serum and added in duplicate at a rate of 100 //I to individual wells except for two 
wells in each plate which served as background controls. The plates were 
incubated for 2 h at room temperature followed by 3 washes with ELISA wash 
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buffer. Rabbit anti-sheep IgG (H+L) conjugated to horseradisli peroxidase 
(Kirkegaard & Perry Laboratories Inc. (KPL), Gaithersburg, MD) was diluted 1:2000 
in PBS containing 1% horse serum and added at a volume of 100 //I/well. Plates 
were incubated for 2 h at room temperature and then washed as described 
previously. One hundred //I of one component ABTS (2.2'-azino-di 3-ethyl-
benzthiazoline sulfonate) peroxidase substrate (KPL) was added to each well. 
When the optical denisity (OD) value of the positive control sample reached 0.8 in a 
Bionetics, LBI-30 spectrophotometer (Litton, Charleston, SC), color development 
was stopped by adding 100//I of peroxidase stop solution (KPL) to each well. 
Absorbance values were determined with an automatic microplate reader 
(Dynatech MR600 microplate reader, Dynatech) with a test filter wavelength of 
490 nm. Absorbance values of individual samples were determined by subtracting 
the OD value of control wells from the OD value of each sample. Discriminant 
analysis (Johnson and Wichern, 1988) was used to set the threshold for negative 
and positive samples. A baseline OD reaction was established using 30 known 
negative serum samples that gave a corrected OD range of 0.000 to 0.150. 
Corrected OD values of 0.250 or greater were considered positive for the present 
ELISA data. Values expressed by various dilutions in ELISA were also analysed. 
Dilutions of 1:200 gave the most consistent OD values and were used to indicate 
the OD values of each serum sample. The values expressed represent the mean 
of two replications. 
Western Immunoblot Assay 
Preparation of antigens 
Cells and viruses were grown as described for the preparation of ELISA 
antigens. When the cytopathic effect Involved approximately 80% of the cell 
monolayer, sterilized glass beads were added to each flask. Virus-infected cells 
were detached from the surface by gently rolling the beads on the flask surface. 
The virus-infected cell preparation was transferred to a centrifuge tube and 
centrifuged at 2000 g for 15 minutes. Each pellet was washed three times in 
DMEM without serum, The virus-infected cell pellet was disrupted in a 10 x pellet 
volume of lysis buffer (pH 8.0, 0.05M Tris, 0.15M NaCI, 0.002M EDTA, 0.5% 
deoxycholate, 0.1% SDS, 1% NP-40, 0.1% sodium azide, 0.1% gelatin, 0.1% 
aprotinin, and 0.1% bovine serum albumin). Each suspension was stirred 
overnight at 4°C and then centrifuged at 2000 g for 15 minutes. The supernatants 
were aliquoted and stored at -70 °C. 
Sodium dodecyl suifate-polyacrylamlde gel electrophoresis (SDS-PAGE) 
A modified Laemmli (1970) procedure was used to separate proteins on a 
discontinuous gel consisting of 4% stacking gel and 13% resolving gel. 
Electrophoresis was carried out on a vertical slab mini-gel apparatus (Bio-Rad 
Laboratories, Richmond, CA) as directed by the manufacturer. Proteins were 
solubilized in sample buffer containing 2% SDS, 4% 2-mercaptoethanol, 0.05% 
bromophenol blue, and 50% glycerol In 0.5M Tris buffer (pH 6.8) at 100°C for 5 
minutes. Each lane was loaded with 8 /vl of an antigen preparation (4 //g protein). 
Prestained SDS-PAGE standards (Bio-Rad) were also included on each gel. The 
following proteins were included as molecular size standards: lysozyme (18,500), 
soybean trypsin inhibitor (27,500), carbonic anhydrase (32,500), ovalbumin 
(49,500), bovine serum albumin (80,000), and phosphorylase B (106,000). All gels 
were electrophoresed for 3 h at 150 volts (Model 250/2.5 power supply, Bio-Rad). 
Electrophoretic transfer of proteins 
A trans-blot electrophoretic transfer cell (gel holder dimensions 21x17 cm, 
Bio-Rad) was used following the recommended procedure of the manufacturer. 
Viral and cellular proteins along with molecular weight markers separated in gels 
were electrophoretically transferred to 0.45 // nitrocellulose membranes (Bio-Rad) 
immediately following SDS-PAGE. Transfer was carried out at 4®C for 90 minutes 
at 100 volts in transfer buffer consisting of 25mM Tris, 192mM Glycine (pH 8.3) and 
20% v/v methanol. 
Western immunoblot assay procedure 
The nitrocellulose membrane containing separated proteins was blocked 
with 1% gelatin in TBS, (500mM NaCI, 20mM Tris, pH 7.5) overnight at 4°G. The 
membrane was washed for three 5 minutes cycles in TBS containing 0.05% Tween 
20 (TTBS) on a rocker platform. Antiserums against all the four viruses were 
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diluted 1:400 in TTBS containing 1% gelatin. Each membrane was incubated with 
antiserum against a single virus for 1 h at room temperature on a rocker platform. 
The membrane was again washed as described previously. Peroxidase-Iabeled 
rabbit anti-sheep IgG (H+L) antibody (KPL) was diluted 1:4000 in TTBS containing 
1% gelatin and the membrane was incubated in this solution for 1 h at room 
temperature on rocker platform. The membrane was again washed as described 
previously. Each membrane was immersed in one component TMB (3,3',5,5'-
tetramethylbenzidine) membrane peroxidase substrate (KPL). The color reaction 
developed in 2-3 minutes and was stopped by three brief washes in deionized 
water. Apparent molecular weights were determined by comparison with the 
protein standards according to standard procedures (Hames, 1981). 
Radioimmunoprecipitation Assay (RIPA) 
Preparation of antigens 
Madin-Darby bovine kidney cells were grown in 75 cm^ flask as described 
for the preparation of ELISA antigens. Cell monolayers were infected with each 
virus at a MOI of one PFU/cell and incubated at 37°C. At 16 h postinfection (PI), 
the medium was replaced with methionine-free MEM and the cells were incubated 
at 37°C for 1 h. The medium was replaced with fresh methionine-free MEM 
containing 100uCi/ml ^®S-methionine (ION Biomedicals, Inc., Irvine, OA). Twenty 
hours after the addition of the ^^S-methionine, the cell monolayer was scraped with 
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a sterile plastic scraper from tlie flask and pelleted by centrifugation at 300 g for 15 
minutes. The cellular pellet containing labelled proteins was then disrupted with 
one ml of lysis buffer (50mM NaCI, 50mM Tris, 5mM EDTA, 1% Triton X-100, and 
1mM phenylmethylsulfonyl fluoride). The lysis buffer and cellular pellet mixture was 
vortexed vigorously for one minute and placed on ice for three minutes. The 
remaining cellular residue was removed by centrifugation at 300 g for 15 minutes. 
Mock infected lysate was also prepared using the same protocol. The lysates were 
stored at -70 °C until needed. 
Radioimmunopreclpitation procedure 
Fifty fj\ of appropriate lysate was mixed with 50 //I of serum (1:10 dilution in 
PBS) and incubated overnight at 4°C. A 30% dilution of equal volumes of protein 
A and G coated Sepharose beads (Sigma) was made in PBS. Immune complexes 
were adsorbed by the addition of 50 ij\ of the Sepharose bead suspension and 
incubation for 2 h at 4°C. The antigen-antibody complexes/protein A and G 
Sepharose beads were then washed 6 times with PBS by use of a microcentrifuge 
(Model 235C, Fisher Scientific) and resuspended in 50 jt/l sample buffer. The 
suspension was boiled at 100° C for 5 minutes and then stored at -70 °C until 
needed. Mock-infected lysate was prepared in a similar manner. 
SDS-PAGE 
Five jt/l aliquots of antigen, control cell antigen, and molecular weight 
markers (C14, Amersham, Arlington Heights, IL) were loaded in individual wells of 
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the miniature slab gel. The gel was electrophoresed as described previously. The 
gel was destalned for 1 h In a solution containing 25% methanol and 7.5% acetic 
acid in deionized water. The destaining solution was decanted and replaced with 
autoradiography enhancer (New England Nuclear, Boston, MA) for 30 minutes. 
The gel was transferred to deionized water for another 30 minutes. Finally, the gel 
was dried under vacuum, exposed to X-OMAT film (Eastman Kodak Company, 
Rochester, NY), and placed at -70°C for 3 to 4 days. The films were processed 
using Kodak RP X-OMAT processor (Eastman Kodak Company, Rochester, NY) 
and observed. 
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RESULTS 
Hyperimmune sera raised against the four paramyxoviruses were subjected 
to HI tests, ELISAs, Western Immunoblottings and RIPAs to determine antigenic 
interrelationships. The levels of antibodies, as determined by HI tests, indicated 
that the sheep responded against all the four viruses (Figure 1). The antibody 
titers were detectable at week 3 following vaccination. There was not much 
change in antibody titers between the 3rd and 6th week. Following the booster 
injection administered at week 6, the antibody titers were higher at week 8. 
Antibody titers did not change appreciably between week 8 and week 9. 
Figure 2 shows the HI antibody titers of the sera when tested against BPI-3 
virus. Bovine PI-3 virus antiserum showed the highest antibody titer while HPI-3 
virus antiserum reacted with a similar pattern but with lower titers. Antibodies 
reactive with BPI-3 virus were detectable in Sendai virus antiserum at week 3 and 
there was a rise in titer after the booster dose at week 6. Antiserum against SV-5 
did not react with BPI-3 virus at week 3. However, some level of antibody was 
detectable at week 4 and thereafter. There was no increase in antibody titer after a 
booster dose. 
Figure 3 shows the HI activity of serums when tested against HPI-3 virus. 
All antisera had detectable antibody activity at week 3. Almost identical patterns 
and antibody levels were associated with antisera raised against HPI-3 and BPI-3 
viruses. Antiserums against all the viruses showed an Increase in antibody titers 
Figure 1. The graph shows the immune response of sheep as detected by HI 
tests following immunization with several paramyxoviruses. Viruses 
used were BPI-3, HPI-3, Sendai, and SV-5. Two sheep were 
immunized subcutaneously (SC) with each virus and a booster dose 
was administered SC at week 6. HI antibody titers are expressed as 
mean Logg of both samples. 
Figure 2. The graph shows HI reactivity fqr BPI-3 virus of serums from sheep 
immunized with several paramyxoviruses. Viruses used were BPI-3, 
HPI-3, Sendai, and SV-5. Two sheep were immunized SC with each 
virus and a booster dose was administered SC at week 6. HI 
antibody titers are expressed as mean Logg of both samples. 
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Figure 3. The graph shows HI reactivity for HPI-3 virus of serums from sheep 
immunized with several paramyxoviruses. Viruses used were BPI-3, 
HPI-3, Sendai and SV-5. Two sheep were immunized SC with each 
virus and a booster dose was administered SC at week 6. HI 
antibody titers are expressed as mean Logs of both samples. 
Figure 4. The graph shows HI reactivity for Sendai virus of serums from sheep 
immunized with several paramyxoviruses. Viruses used were BPI-3, 
HPI-3, Sendai, and SV-5. Two sheep were immunized SC with each 
virus and a booster dose was administered SC at week 6. HI 
antibody titers are expressed as mean Logg of both samples. 
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after booster dose however, minimal response was observed against SV-5 
antiserum. 
The HI reactivity of antisera for Sendai virus is shown in Figure 4. Antisera 
against BPI-3 and HPI-3 viruses showed the presence of cross reactive antibodies 
after primary immunization and the titers increased after a booster dose. However, 
the titers were lower than the Sendai virus antiserum. The antibody response to 
SV-5 was obsen/ed only after booster dose but the level of antibody was very low. 
Figure 5 shows the reactivity of BPI-3, HPI-3, Sendai virus and SV-5 antisera 
when tested against SV-5 in HI tests. Only the homologous antiserum 
demonstrated appreciable HI activity. Antiserum against other viruses reacted with 
SV-5 but the titers were very low. 
The results of ELISA that measured the level of antibodies reactive with BPI-
3 virus are presented in Figure 6. The greatest reactivity was observed with 
homologous antiserum but there was appreciable reactivity with HPI-3 virus 
antiserum particularly following the booster immunization. Surprisingly, no increase 
in BPI-3 virus antibodies was recorded after the booster dose whereas a rise in 
antibody titer was observed in case of HPI-3 virus antiserum. Sendai virus and SV-
5 antibody titers did not rise above the threshold although there was slight increase 
in the antibody titer of Sendai virus antiserum after the booster dose. 
Reactivity of various paramyxovirus antisera against HPI-3 virus when tested 
in ELISA is shown in Figure 7. Antiserum against BPI-3 and HPI-3 viruses showed 
Figure 5. The graph shows HI reactivity for SV-5 of serums from sheep 
immunized with several paramyxoviruses. Viruses used were BPI-3, 
HPI-3, Sendai, and SV-5. Two sheep were immunized SC with each 
virus and a booster dose was administered SC at week 6. HI 
antibody titers are expressed as mean Logg of both samples. 
Figure 6. The graph shows the reactivity of BPI-3 virus antigens with serums 
from sheep immunized with several paramyxoviruses as measured 
with an ELISA. The viruses used for immunization were BPI-3, HPI-3, 
Sendai, and SV-5. Two sheep were immunized SC with each virus 
and a booster dose was administered SC at week 6. Antibody titers 
are expressed as the mean optical density of both samples. 
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an increase in antibody titers by week 3 following immunization. The titers declined 
by week 6 at which time the titer of HPI-3 virus antiserum was higher than BPI-3 
virus antiserum. When the booster dose was given at week 6, there was rise in 
antibody titers of both BPI-3 and HPI-3 antisera as detected at week 8. Both the 
sera showed declining titers at week 9. Sendai virus and SV-5 antiserum failed to 
demonstrate appreciable reactivity for HPI-3 virus throughout the period of 
experimentation. 
Figure 8 shows the reactivity of the various paramyxovirus antisera when 
tested against Sendai virus in ELISA. Antisera against Sendai, BPI-3 and HPI-3 
viruses reacted at week 3, the antiserum against Sendai virus showing the highest 
titer. There was a slight decline in the titers of BPI-3 and HPI-3 virus antisera at 
week 4, after which, the titers increased slightly by week 6. Secondary 
immunization failed to increase levels of antibody very much. SV-5 antiserum 
demonstrated no reactivity throughout the period of experimentation. 
Figure 9 shows the reaction of SV-5 antigens with the various paramyxovirus 
antisera. Reactivity was observed only with the homologous SV-5 antiserum. 
Paramyxovirus antigens were reacted with BPI-3 virus hyperimmune serum 
in Western immunoblot assays. Results are shown in Figure 10. The antiserum 
detected P, HN, NP, F and M proteins of BPI-3 virus and also reacted with HN, NP, 
F and M proteins of HPI-3 virus. The antiserum also reacted with the NP protein of 
Sendai virus but reactivity with SV-5 antigens could not be discerned. 
Figure 7. Tlie graph shows the reactivity of HPI-3 virus antigens with serums 
from sheep immunized with several paramyxoviruses as measured 
with an ELISA. The viruses used were BPI-3, HPI-3, Sendai, and SV-
5. Two sheep were immunized SC with each virus and a booster 
dose was administered SC at week 6. Antibody titers are expressed 
as the mean optical density of both samples. 
Figure 8. The graph shows the reactivity of Sendai virus antigens with serums 
from sheep immunized with several paramyxoviruses as measured 
with an ELISA. The viruses used for immunization were BPI-3, HPI-3, 
Sendai, and SV-5. Two sheep were immunized SC with each virus 
and a booster dose was administered SC at week 6. Antibody titers 
are expressed as the mean optical density of both samples. 
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Figure 9. The graph shows the reactivity of SV-5 antigens with serums from 
sheep immunized with several paramyxoviruses as measured with an 
ELISA. The viruses used were BPI-3, HPI-3, Sendai, and SV-5. Two 
sheep were immunized SC with each virus and a booster dose was 
administered SC at week 6. Antibody titers are expressed as the 
mean optical density of both samples. 
Figure 10. Immunoblot analysis shows the reactivity of several paramyxoviruses 
with BPI-3 virus hyperimmune serum. Lane 1 = molecular weight 
markers; Lane 2= MDBK cell lysate; Lane 3= BPI-3 virus; Lane 4= 
HPI-3 virus; Lane 5= Sendai virus; Lane 6= SV-5. After transfer from 
gel (13%) to nitrocellulose membrane, the immunoblot was probed 
with BPI-3 virus antiserum (1:400), followed by rabbit anti sheep IgG 
(1:4000) conjugated to peroxidase. The substrate 3,3',5,5'-
tetramethylbenzidine was used to visualize the protein bands. 
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The HPI-3 virus antiserum was found to be reactive with HN, NP, F, and IVI 
proteins of HPI-3 virus (Figure 11). Reactivity was also observed with the HN, NP, 
F and M proteins of BPI-3 virus. There was no apparent reactivity with the proteins 
of Sendai virus and SV-5. 
Sendai virus antiserum reacted with P, HN, NP, F and M proteins of Sendai 
virus (Figure 12). It was also found to be reactive with the HN protein of BPI-3 
virus but no apparent reactivity with SV-5 or HPI-3 virus structural antigens was 
observed. 
Figure 13 shows the reaction of SV-5 antiserum with paramyxoviruses 
included in the study. The serum reacted with the HN, NP, F, P and M proteins of 
SV-5 virus. There was no apparent reactivity with any of the heterologous viruses. 
The antigenic interrelationships among different paramyxoviruses were also 
explored by comparing the polypeptide pattern as detected by RIPA. The BPI-3 
virus antiserum was found reactive with the P, HN, NP, F and M proteins of BPI-3 
virus (Figure 14). It also reacted with the P, HN, NP, F and M proteins of HPI-3 
virus. The serum also recognized the P, NP, and M proteins of Sendai virus and 
NP protein of SV-5. 
Figure 15 shows the reactivity of HPI-3 virus antiserum with the various 
paramyxoviruses. It reacted with the P, HN, NP, F and M proteins of HPI-3. The 
serum also precipitated P, HN, NP, F and M proteins of BPI-3 virus. Reactivity was 
also observed with the P and NP proteins of Sendai virus and NP protein of SV-5. 
Figure 11. Immunoblot analysis shows the reactivity of several paramyxoviruses 
with HPI-3 virus hyperimmune serum. Lane 1 = molecular weight 
markers; Lane 2= MDBK cell lysate; Lane 3= BPI-3 virus; Lane 4= 
HPI-3 virus; Lane 5= Sendal virus; Lane 6= SV-5. After transfer from 
gel (13%) to nitrocellulose membrane, the Immunoblot was probed 
with HPI-3 virus antiserum (1 ;400), followed by rabbit anti sheep IgG 
(1:4000) conjugated to peroxidase. The substrate 3,3',5,5'-
tetramethylbenzidine was used to visualize the protein bands. 
Figure 12. Immunoblot analysis shows the reactivity of several paramyxoviruses 
with Sendai virus hyperimmune serum. Lane 1 = molecular weight 
markers; Lane 2= MDBK cell lysate; Lane 3= BPI-3 virus; Lane 4= 
HPI-3 virus; Lane 5= Sendai virus; Lane 6= SV-5. After transfer from 
gel (13%) to nitrocellulose membrane, the immunoblot was probed 
with Sendai virus antiserum (1:400), followed by rabbit anti-sheep IgG 
(1:4000) conjugated to peroxidase. The substrate 3,3',5,5'-
tetramethylbenzidine was used to visualize the protein bands. 
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Figure 13. Immunoblot analysis shows the reactivity of several paramyxoviruses 
with SV-5 hyperimmune serum. Lane 1 = molecular weight markers; 
Lane 2= MDBK cell lysate; Lane 3= BPI-3 virus; Lane 4= HPI-3 
virus; Lane 5= Sendai virus; Lane 6= SV-5. After transfer from gel 
(13%) to nitrocellulose membrane, the immunoblot was probed with 
SV- 6 antiserum (1:400), followed by rabbit anti-sheep IgG (1:4000) 
conjugated to peroxidase. The substrate 3,3',5,5'-
tetramethylbenzidine was used to visualize the protein bands. 
Figure 14. Radioimmunoprecipitation analysis shows the reactivity of several 
paramyxoviruses with BPI-3 virus hyperimmune serum. Lane 1 = 
molecular weight markers; Lane 2= MDBK cell lysate; Lane 3= BPI-3 
virus; Lane 4= HPI-3 virus; Lane 5= Sendai virus; Lane 6= SV-5. 
Viruses grown on MDBK cells were labeled with ^^S-methionine. The 
labeled antigens were reacted with BPI-3 virus hyperimmune serum 
(1:10). Antigen-antibody complexes were collected with protein A and 
G coated Sepharose beads. The gel (13%) containing separated 
polypeptides was dried and exposed to X-OMAT film. 
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Figure 15. Radlolmmunoprecipitatlon analysis shows the reactivity of several 
paramyxoviruses with HPI-3 virus hyperimmune serum. Lane 1 = 
molecular weight markers; Lane 2= MDBK cell lysate; Lane 3= BPI-3 
virus; Lane 4= HPI-3 virus; Lane 5= Sendai virus; Lane 6=SV-5. 
Viruses grown on MDBK cells were labeled with ^®S-methionine. The 
labeled antigens were reacted with HPI-3 virus hyperimmune serum 
(1:10). Antigen-antibody complexes were collected with protein A and 
G coated Sepharose beads. The gel (13%) containing separated 
polypeptides was dried and exposed to X-OMAT film. 
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Sendai virus antiserum reacted with the P, HN, NP, and M proteins of 
Sendai virus (Figure 16). It also reacted with the P, HN, NP, and M proteins of 
HPl-3 virus only. 
SV-5 antiserum reacted with the HN, NP, F, P and M proteins of SV-5 virus 
(Figure 17). It also precipitated the NP protein of HPI-3 virus. 
Figure 16. Radioimmunoprecipitation analysis shows the reactivity of several 
paramyxoviruses with Sendai virus hyperimmune serum. Lane 1 = 
molecular weight markers; Lane 2= MDBK cell lysate; Lane 3= BPI-3 
virus; Lane 4= HPI-3 virus; Lane 5= Sendai virus; Lane 6=SV-5. 
Viruses grown on MDBK cells were labeled with ^®S-methionine. The 
labeled antigens were reacted with Sendai virus hyperimmune serum 
(1:10). Antigen-antibody complexes were collected with protein A and 
G coated Sepharose beads. The gel (13%) containing separated 
polypeptides was dried and exposed to X-OMAT film. 
Figure 17. Radioimmunoprecipitation analysis shows the reactivity of several 
paramyxoviruses with SV-5 hyperimmune serum. Lane 1 = molecular 
weight marl<ers; Lane 2= MDBK cell lysate; Lane 3= BPI-3 virus; 
Lane 4= HPI-3 virus; Lane 5= Sendai virus; Lane 6= SV-5. Viruses 
grown on MDBK cells were labeled with ^®S-methionine. The labeled 
antigens were reacted with SV-5 hyperimmune serum (1:10). 
Antigen-antibody complexes were collected with protein A and G 
coated Sepharose beads. The gel (13%) containing separated 
polypeptides was dried and exposed to X-OMAT film. 
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DISCUSSION 
This study utilized polyclonal viral antiserums produced in lambs and reflects 
the recognition of antigens associated with several paramyxoviruses (BPI-3, HPI-3, 
Sendai and SV-5) by this animal. These antiserums allowed the study of the 
antigenic interrelationships among these viruses by the application of several assay 
systems (HI, ELISA, WIA, RIPA). Polyclonal antiserums have been employed in HI 
and complement fixation tests by other workers to observe antigenic relationships 
(Ketler et al., 1961; Abinanti et al., 1961). In addition, virus epitope specific MAbs 
have been utilized in HI tests, ELISA and RIPA (Goswami and Russell, 1983; 
Coelingh et al., 1986, 1987, 1988; Ray and Compans, 1986; Ito et al., 1987; 
Rydbeck et al., 1987, 1988; Klippmark et al., 1990). In general, these 
experimentations have demonstrated that BPI-3 and HPI-3 viruses are closely 
related antigenically. Sendai and HPI-3 viruses share antigens but are less closely 
related. SV-5 has not been demonstrated to be antigenically related to HPI-3 virus. 
Extensive antigenic relationships between BPI-3 and HPI-3 viruses were 
observed in the present experimentation in confirmation of previous reports. 
Polyclonal antiserums demonstrated minimal differences in HI titers when reacted 
with the homologous and heterologous viruses in our study and those reported by 
Coelingh et al. (1988). These findings would indicate that HN protein of the two 
viruses share common epitopes. 
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The hemagglutination inhibiting activity of BPI-3 and HPI-3 virus antiserums 
for homologous and heterologous viruses is particularly interesting in light of 
previously reported observations. Antigenic relationships between the HN proteins 
of BPI-3 and HPI-3 viruses have been demonstrated by other workers using MAbs 
(Coellngh et al., 1986; Ray and Compans, 1986; Coelingh et al., 1988; Klippmark 
et al., 1990). These workers observed that the HN protein of BPI-3 and HPI-3 
viruses differ to a major extent in their reactivities toward MAbs although there are 
a few common epitope(s) present in the HN protein of these viruses. The 
homology regions were observed between residues 91 to 125, 202 to 291, 306 to 
340, 349 to 387 and 404 to 521 (Coelingh et al., 1986). In addition to polypeptide 
homology, 3 to 4 glycosylation sites on HN proteins in BPI-3 and HPI-3 viruses are 
conserved (Coelingh et al., 1986). 
ELISA results also demonstrated crossreactivity between the two strains of 
PI-3 virus. While the level of reactive antibodies present in HPI-3 virus antiserum 
against BPI-3 virus was much lower, the reactivity of BPI-3 virus and HPI-3 virus 
antiserums with HPI-3 virus was similar. This one-way reactivity may reflect the 
composition and relatedness of reactive epitopes present on both these viruses. 
Other possible reason could be that antibodies produced against HPI-3 virus are of 
low affinity and did not adhere well to BPI-3 virus antigens. HI tests indicate that 
antibodies against HN proteins of both the viruses react similarly with each other. 
However, there are some epitopic differences in the other structural proteins of 
these viruses as observed by antibody titers in ELISA. 
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In WIAs and RIPAs, antiserums of BPI-3 and HPI-3 viruses recognized the 
same structural proteins in the homologous as well as heterologous systems. This 
crossreactivity has previously been demonstrated for HN, NP, F and M proteins by 
Rydbeck et al., (1987) using MAbs against HPI-3 viral proteins in RIPA. However, 
results of ELISA using HPI-3 virus antiserum and BPI-3 virus antigens Indicated 
rather distinct antigenic differences between these viruses. This variation could be 
explained by the nature of the assays in that ELISA procedure reflects the total 
spectrum and quantity of antibodies present in a serum. Indirectly, these results 
suggest distinct differences between the epitopes of certain viral proteins as 
reported by other workers (Rydbeck et al., 1987; Klippmark et al., 1990). 
Antigenic relationships between Sendai virus and PI-3 viruses were also 
demonstrated. These viruses apparently share common antigens associated with 
their HN proteins since HI activity was observed between Sendai virus, the two PI-3 
viruses and their antiserums. However, one way crossreactivity was observed 
between the Sendai virus antiserum and the HN protein of BPI-3 virus in WIA. 
Apparently, the lamb recognizes an epitope in Sendai virus that is crossreactive 
with that of BPI-3 virus; on the other hand, the lamb does not recognize a 
comparable epitope on BPI-3 virus. 
Recognition of certain viral epitopes by lambs may account for the difference 
of results in present studies. For instance, Sendai virus antiserum reacted with 
certain viral antigens of BPI-3 and HPI-3 viruses in ELISA, but this reactivity was not 
reciprocated. The possibility exists that the lambs recognized common epitopes 
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but that the antibodies were of differing affinity. Low affinity antibodies may not 
adhere and thus not be detected in ELISA. However in RIPA, we were able to 
demonstrate the reactivity of Sendai virus antiserum with P, HN, NP, F and M 
proteins of HPI-3 virus but no reactivity was observed with BPI-3 virus. Studies 
have been conducted by other workers using MAbs in RIPA to describe the 
crossreactive proteins of HPI-3 virus and Sendai virus. HPI-3 virus MAbs reacted 
with the NP polypeptide of Sendai virus (GoswamI and Russell, 1983; Ito et al., 
1987) and other HPI-3 virus MAbs reacted with the F and M (GoswamI and Russell, 
1982) proteins of Sendai virus. 
In this study, results of WIA and RIPA did not correlate. These variations 
could be associated with differences in the methodologies of these assays. 
Although RIPA is considered more sensitive mainly due to radioactive material used 
in the system, there can also be non-specific precipitation of viral proteins. In 
RIPA, antibodies with low affinity for certain antigen(s) may be eliminated before 
precipitating antigen (s) while in WIA, the antigens are transferred to the 
nitrocellulose membrane and then reacted with the antibodies. Proteins not 
detected by WIA may be present in small amounts or not transferred efficiently 
enough to be detected in our system. This emphasizes that more than one 
methodological approach is necessary for the detection of viral polypeptides. 
In RIPA, antiserums against BPI-3 virus and HPI-3 virus precipitated NP 
protein of all the viruses included in these studies. Antigenic relationships between 
the NP proteins of HPI-3 virus with that of Sendai virus (Sanchez et al., 1988) and 
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SV-5 (Goswami and Russell, 1983) has already been reported. Conserved regions 
in NP protein probably reflect a common protein function in each of these 
paramyxoviruses. For example, Deshpande and Portner, (1985) have reported two 
topologically distinct epitopes on the NP protein of Sendai virus that were -
associated with the transcriptional activity during viral replication. 
Limited crossreactivity was observed between SV-5 and other viruses. While 
some crossreactivity was noted in the HI test, this is probably non-specific due to a 
variety of factors present in the antiserums. No reactivity between SV-5 and any of 
other viruses was observed In ELISA or WIA. However, BPI-3 and HPI-3 viruses 
antiserums precipitated the NP protein of SV-5 in RIPAs while SV-5 antiserum 
reacted with NP protein of HPI-3 virus only. 
The experimentation demonstrated that the immune system of lambs 
recognizes antigens associated with the major structural proteins of 
paramyxoviruses. These antiserums confirm previously reported observations that 
HPI-3 virus and Sendai virus share a variety of common antigens. Results of this 
study indicate that those relationships extend to BPI-3 virus. These antigenic 
relationships are primarily associated with the HN and NP proteins. The fact that 
these proteins are commonly associated with the protective immunity to the 
paramyxoviruses suggest that there may be potential for use of these viruses to 
use in heterotypic immunization. In theory, one virus could be utilized to prime an 
animal for a secondary immune response to another virus. This approach might 
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be utilized for overcoming the antigen blocking effect of maternal antibodies against 
PI-3 virus in young lambs. 
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PART II. IMMUNOGENICITY OF PARAMYXOVIRUS VACCINES IN LAMBS 
WITH PARAINFLUENZA-3 VIRUS MATERNAL ANTIBODIES 
86 
ABSTRACT 
Immunization of young animals against parainfluenza virus type 3 (PI-3) is a 
major problem due to the presence of maternal antibodies that interfere with an 
active immune response. The objective of this experimentation was to develop a 
vaccine that would overcome that blocking effect. Lambs with variant levels of PI-3 
antibodies were vaccinated with three different paramyxoviruses that possessed 
antigenic relationships; the viruses were bovine PI-3 virus, human PI-3, and Sendai 
virus. In the first experiment, a large quantity of semi-purified virus was 
incorporated in an oil adjuvant and administeired to lambs. All three viruses 
induced a detectable immune response to the homologous virus, as detected by HI 
tests. The human PI-3 viral vaccine induced an increased titer of antibodies 
against the bovine strain. In a second experiment, a smaller quantity of the viruses 
(25 or 50 f j g )  was adjuvanted with aluminum hydroxide and administered to groups 
of lambs. Primary immunization failed to induce a detectable response to bovine 
PI-3 virus. When these animals were administered a booster dose of bovine PI-3 
virus vaccine, there was a significant increase in antibody titers. Groups of lambs 
that had not been vaccinated or administered a single dose of bovine PI-3 virus or 
human PI-3 virus or two doses of bovine PI-3 virus vaccine were challenged with 
an ovine strain of PI-3 virus. Most lambs shed virus and developed signs of clinical 
disease but the severity (degree and duration) varied. Clinical signs were most 
dramatic in the unvacclnated controls. Lambs in the once-vaccinated bovine PI-3 
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virus group were also markedly affected but the disease was much less severe in 
the once-vaccinated human PI-3 virus and double vaccinated bovine PI-3 virus 
groups. One lamb from each group was necropsied on day 8 following challenge. 
Pathological findings confirmed our previous observations that BPI-3 virus (two 
doses) and HPI-3 virus (single vaccination) could induce a protective immune 
response in the presence of maternal antibodies against PI-3 virus. 
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INTRODUCTION 
Viral pneumonia of animals is an infectious disease characterized clinically 
by varying degrees of severity. The present concept of the etiology of the disease 
is that it is a complex syndrome, involving stress and viral and secondary bacterial 
infections. The evidence for viruses as primary etiological agents is based on virus 
Isolation, serological evidence of virus infection and pathological lesions of viral 
pneumonia. In sheep, a variety of viral pathogens have been enumerated including 
respiratory syncytial virus, parainfluenza type 3 (PI-3) virus, bovine viral diarrhea 
virus and adenoviruses etc. (Alley, 1975; Alley et al., 1975; Davies and Humphreys, 
1977; Thurley et al., 1977; Davies, 1980). Among these, parainfluenza type 3 (PI-3) 
virus is considered an important factor in the initiation of infection (Alley and Clarke, 
1977). The surveys on the basis of isolation and serology indicates that PI-3 virus is 
common and wide-spread in New Zealand (Davies, 1980), Scotland (Jones et al., 
1979), the United States ( Lehmkuhl and Cutlip, 1983) and Canada (Durham and 
Hassard, 1990). Clinical disease caused by PI-3 virus is variable in severity and the 
most important consequence is the bacterial pneumonia which may ensue. The 
virus suppresses resistance mechanisms in the respiratory tract and thereby 
predisposes to infection with bacterial agents (Sharp et al., 1978; Davies et al., 
1981). Secondary bacterial invasion and environmental factors, usually inadequate 
ventilation and housing, complicate the disease. Although prophylactic vaccines 
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against these viruses and preventive programs involving management practices 
have been developed, respiratory tract infections still exist almost unchanged. 
A variety of monovalent, multivalent, and killed or live PI-3 virus vaccines are 
available and used without much success In preventing the respiratory tract 
infections in young animals. Immunization of the young lamb is not readily 
accomplished due to the presence of anti-viral antibodies acquired from the ewe. 
Antigenicity of commercial vaccines administered by a parenteral route are 
effectively blocked by these maternal antibodies resulting in a very limited immune 
response (Bogel and Llebelt, 1963). Multiple vaccinations are required to immunize 
animals with colostrally acquired maternal antibodies. 
One approach to eliminate the blocking of vaccine antigens by maternal 
antibodies is to use a heterotypic virus vaccine. In animals, measles virus vaccine 
has been successfully used to immunize puppies against canine distemper virus 
infection in the presence of maternal antibodies (Appel et al, 1984). This approach 
has also been employed to prevent human PI-3 virus infection by the use of bovine 
PI-3 virus vaccine. Coelingh et al. (1988) demonstrated that non-human primates, 
with a low level of maternal antibodies (<2 HI titer), resisted challenge by human 
PI-3 virus following live bovine PI-3 virus vaccination. 
The objective of this experimentation was to develop a vaccine that could 
induce immune response In lambs with some level of maternal antibodies against 
PI-3 virus. In the present studies, we used bovine PI-3, human PI-3 and Sendai 
virus vaccines to immunize young lambs that possessed variant levels of anti-PI-3 
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virus maternai antibodies. Immune responses were evaiuted at varying time 
intervals after immunization with HI tests. Protection induced by bovine PI-3 virus 
(single and twice vaccinations) and human PI-3 virus vaccine in lambs was also 
studied by challenging them with live ovine PI-3 virus. 
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MATERIALS AND METHODS 
Viruses, Cells, and Medium 
The viruses used in the experiment and their sources were as follows: 
1. Bovine PI-3 virus, American Tissue Culture Collection (ATCC) # VR-281. 
2. Human PI-3 virus- - courtesy Dr. Robert C. Chanock, National Institutes of 
Health, Bethesda, MD. 
3. Sendai virus- - ATCC # VR-105. 
A primary cell line of ovine fetal turbinate (OFT) cells (courtesy Dr. Howard 
Lehmkuhl, National Animal Disease Center (NADC), Ames, lA) were used, unless 
otherwise mentioned, to propagate all three viruses. Growth medium used was 
Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% ovine serum 
(NADC, Ames, lA) and 1% L-glutamine (GIBCO Laboratories, Grand Island, NY). 
Gentamicin sulfate (Schering Corporation, Kenilworth, NJ) was added at the rate of 
5 mg/100 ml of the medium. 
Propagation of Viruses 
Primary virus culture 
Madin-Darby bovine kidney (MDBK) cells were used to prepare primary 
cultures of each virus except Sendai virus which was propagated as described 
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later. MDBK cells were grown in polystyrene 150 cm^ flasks (Corning Glass Works, 
Corning, NY) containing 30 ml DMEM supplemented with 10% fetal calf serum 
(PCS) and 5 mg/100 ml gentamicin sulfate. A confluent cell monolayer was 
Infected with each virus at a multiplicity of infection (MOI) of 5 plaque forming units 
(PFU) per cell and the virus was allowed to adsorb for 60-90 minutes at 37°C in an 
incubator with 5% CO;. After viral adsorption, the inoculum was removed and 
replaced with 30 ml of DMEM containing 1% PCS and 5 mg/100 ml of gentamicin 
sulfate. When cytopathic effect was evident in about 80% of the monolayer (3-5 
days), the flasks were frozen at -70°C. The flasks were thawed at room 
temperature, the suspensions were aliquoted and stored at -70 °C. 
Cultivation of Sendai virus 
A stock preparation of Sendai virus was diluted (1:512, 1 hemagglutination 
(HA) titer/ml) in phosphate buffered saline (PBS, pH 7.2, 14mM potassium 
phosphate monobasic, 26mM potassium chloride, 8mM sodium phosphate dibasic, 
Sigma Chemical Company, St. Louis, MO). Ten specific-pathogen-free 
embryonated eggs (9 days old) were used to propagate Sendai virus. The eggs 
were candled to observe the viability of the embryo. An area of the chorioallantoic 
membrane that was free of large blood vessels was marked with a lead pencil. 
The marked area of each egg was swabbed with 70% alcohol. A small hole was 
made through the shell at the upper extremity over the air cell using 18 guage 1" 
needle. Eggs were inoculated with 0.1 ml of the virus suspension by one ml 
93 
tuberculin syringe fitted with 27 guage 1/2" needle. The holes were closed with 
paraffin and eggs were incubated at 37°C In an Incubator with humid environment. 
Eggs were candled daily to observe for the viability of the embryos. After 72 hours 
(h), the eggs were placed In a refrigerator at 4°C for 3 h. 
To collect the allanto-amnlotic fluid, egg shells were swabbed with 70% 
alcohol. Egg shells over the air cell were cracked and removed using sterile 
forceps and scissors as were the allanto-amniotic membranes. Allanto-amnlotic 
fluid (10-15 ml) was collected with a sterile glass pipette. Fluid from each egg was 
pooled in plastic tubes and centrifuged at 300 g for 30 minutes. Supernatant fluid 
was collected and the sterility was checked by culturing on blood agar plates with 
incubation at 37°C for 48 h. Presence of virus was determined by a 
hemagglutination (HA) test. The virus preparation was aliquoted and stored at 
-70®C. 
Propagation of viruses for vaccine preparation 
Ovine fetal turbinate cells were grown in polystyrene flasks (150 cm^, 
Corning) containing 30 ml of DMEM. When a monolayer of cells had formed, the 
medium was replaced with 5 ml of 0.2% trypsin (Difco Laboratories, Detroit, Ml) 
and incubated at 37°C for 3-5 minutes. Trypsinlzed cells from three flasks were 
transferred to roller bottle (850 cm^, Corning) containing 70 ml of DMEM. The 
roller bottles were incubated at 37°C and rolled at a speed of 16 revolutions/h. 
When the cell monolayer was complete after 24 h, the medium was removed and 
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the cells were infected at a MOI of 1-2 PFU/cell with the primary virus suspension. 
Following virus adsorption in the roller apparatus for 60-90 minutes the virus 
suspension was removed from all roller bottles, replaced with 70 ml DMEM 
(supplemented with 1% ovine serum and 5 mg/100 ml Gentamicin sulfate) and 
incubated at 37°C. When cytopathic effects were evident in 90% of the cell sheet, 
each virus preparation was subjected to three freeze-thaw cycles at -70 °C. The 
virus suspension was centrifuged at 3000 x g to sediment cell debris. The cell free 
supernatant of each virus was stored at -70°C. 
Inactivation of Viruses 
Preparation of binary-etliylenimine 
Binary-ethylenimine (BEI) was used to inactivate the viruses. 
Bromoethylamine (BEA) was converted to BEI by adding 2.65g BEA to 100 ml 
0.175N NaOH (0.7g/100 ml deionized water) warmed to 37°C. The preparation 
was mixed. Initial pH was 12.93. When the pH reached 8.5, the reaction was 
stopped by cooling the solution to 4°C. 
Determination of time required to inactivate virus 
To determine the time required for inactivation of virus, 10 rrii of cell-free 
bovine PI-3 (BPI-3) virus suspension in DMEM with 1% ovine serum was mixed with 
300 /jI of BEI. The suspension was incubated with occasional mixing at room 
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temperature (24 °C). Samples (1 ml) were collected at hourly Intervals up to 6 
hours (h) and at 8 and 24 h. To determine the inactivation rate of virus, MDBK 
cells were grown to produce a monolayer in 96 well flat-bottom microtiter plate 
(Costar Corporation, Cambridge, MA). Ten-fold virus dilutions of the treated virus 
were made in serum free DM EM. Each dilution was added (50 //I) in duplicate to 
wells containing an MDBK cell monolayer. Inactivation of virus was recorded after 
5 days by the absence of cytopathic effect (CPE) or failure to hemadsorb 1% 
guinea pig red blood cells. 
Virus inactivation procedure 
BEI (3% or 3m M) was added to each cell free virus suspension in a sterile 
glass bottle and incubated at room temperature (24 °C) for 8 h. The BE! 
Inactivation was stopped by the addition of a 1M sterile Na-thiosulphate solution 
made in deionized water, at 10% of the volume of the BE! solution used. 
Virus Purification 
Each cell free suspension (about 800 ml) containing inactivated virions was 
centrifuged for 2 h at 100,000 g in a Sorvall T 647.5 rotor. Pelleted virions were 
resuspended in 3 ml of PBS. A discontinuous sucrose gradient consisting of 60% 
(4 ml), 30% (4 ml), and 15% (3 ml) of sucrose in PBS was prepared in a 
polyallomer centrifuge tube (38.5 ml). Resuspended virus was layered onto 
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individual sucrose gradients in separate tubes and centrifuged for 3 h at 100,000 g 
in a Beckman SW 27 rotor. A band present at the interface of the 30 and 60% 
sucrose layers was collected using a sterile Pasteur pipette. This material was 
dialyzed for 24 h at 4°C against four changes of PBS using 12-14000 MW cutoff 
dialysis tubing (Fisher Scientific, Pittsburg, PA). The dialyzed preparations were 
centrifuged for 2 h at 100,000 g in a Beckman SW 27 rotor. The pellets were 
resuspended in 8-10 ml of PBS and stored at -70°C. Presence of virus in the 
preparations was confirmed with an HA test. 
Preparation of Vaccines 
The protein content of each purified virus suspension was determined with 
the bicinchoninic acid (BCA) protein assay procedure (Pierce Laboratories, 
Rockford, IL). Each virus suspension was adjusted to a protein concentration of 1 
mg/ml by the addition of PBS. Gentamicin sulfate was added at a concentration of 
5 mg/100 ml to these preparations and the mixture incubated overnight at 4°C. 
For Experiment I, each virus suspension was emulsified in an equal volume of 
Freund's incomplete adjuvant (Sigma Chemical Company) by use of an 
homogenizer (VirTis "23" homogenizer, VirTis Company, Inc. Gardiner, NY). Each 
vaccine contained 500 //g of viral protein per ml. For Experiments II and III, the 
purified virus suspension was mixed with aluminum hydroxide to make a final 
protein concentration of either 25 jt/g or 50 /yg/ml. The vaccines were prepared 
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shortly before each application and held in a styrofoam box containing an ice 
packet until administered. Booster preparations of BPI-3 virus were prepared in 
aluminum hydroxide to make a final protein concentration of 25 //g/ml. 
Determination of Virus Dose 
The minimum virus dose required to induce an immune response in the 
presence of low hemagglutination inhibition (HI) antibody titer against BPI-3 virus 
was determined in young lambs. Four preparations of vaccine were made in 
aluminum hydroxide as described later. Concentrations of viral protein were either 
25 //g, 50 //g, 100 //g, or 200 //g respectively. Each vaccine preparation was 
administered to a group of four lambs. One ml of vaccine was injected 
subcutaneously (0.5 ml behind each ear). Blood samples were collected on post-
inoculation days (PID) 0, 10, 20, and 34. 
Hemaggiutlnation Inliibition Test 
Standardization of sheep red blood ceiis 
Twenty ml of blood was collected from a healthy sheep into a sterile screw-
cap glass tube containing an equal volume of Alsever's solution (HOmM glucose, 
70mM NaCI, 20mM trisodium citrate, 3mM citric acid). The diluted blood was 
centrifuged at 500 g for 20 minutes. The supernatant was discarded and the 
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packed cells were resuspended to the original volume in normal saline solution. 
The cell suspension was again centrifuged as described before. The packed cells 
were washed 3 times in this manner and resuspended at an appropriate 
concentration in PBS. This suspension when diluted (1:20) In 0.1% sodium 
carbonate solution gave an optical transmittance of 85% at a wavelength of 540 on 
a spectrophotometer (Spectronic 20, Bausch & Lomb). 
Hemagglutination titer of bovine PI-3 virus 
The HA titer of BPI-3 virus for use in HI tests was determined. Two-fold 
serial dilutions of virus (50 //I) were made in PBS (1:2 to 1:4096) in a 96 well round 
bottom microtiter plate (Costar). A standardized suspension of sheep red blood 
cells (SRBCs) was added (50 //I) to each virus dilution. The plate was incubated at 
room temperature for 3 h. The HA titer of virus was recorded as the last dilution 
showing agglutination. For use in the HI test, the virus suspension was diluted in 
PBS to a concentration of 4 HA units/50 //I. 
Hemaggiutination inhibition test procedure 
Hemagglutination inhibition tests were carried-out in round bottom 96 well 
microtiter plates (Costar). Fifty //I of PBS was added to each well of the plate. 
Serum samples (50 //I), Including negative and positive controls, were added to the 
first well of each row. Two-fold-dilutions of each serum were made by mixing the 
suspension thoroughly (10-15 times using a multichannel micropipetter) and 
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transferring 50 //I of this suspension into subsequent wells. Fifty //I of the diluted 
serum was discarded from the last well. Bovine PI-3 virus (4 HA units) was added 
(50 p\) to each well and the plates were incubated at room temperature for 30 
minutes. After this period, standardized SRBCs (50 //I) were added to each well. 
Plates were incubated at room temperature for about 3 h. The HI titer of each 
serum was recorded as the last serum dilution inhibiting agglutination. 
Challenge virus 
The DH-1 isolate of ovine PI-3 (OPI-3) virus isolated from the lungs of a lamb 
with pneumonia was used as challenge virus (courtesy Dr. Howard Lehmkuhl, 
NADC, lA). Ovine fetal turbinate cells were grown in 150 cm^ flasks. When the cell 
monolayer was complete, the cells were infected with third passage OPI-3 virus 
and the flasks incubated at 37°C. When the virally-induced CPE was 
approximately 80%, the flasks were subjected to one freeze-thaw cycle, thawed 
and the suspension utilized for challenge. The inoculum contained 10* * tissue 
culture infectious doses (TCIDgo) per ml. 
All the lambs were challenged with 5 ml of OPI-3 virus suspension 
transtracheally using an 18 guage 1" needle and one ml in each nostril on day 46 
after primary immunization. Each group was housed separately in isolation 
following challenge. 
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Clinical observations and evaluation of immune response 
The lambs were observed for clinical signs twice a day on day 0 through 
day 8, 11, and 14. Observations included feed in-take, activity, nasal discharge 
and respiratory distress. Rectal temperature of all the lambs was also recorded on 
the same days using a clinical thermometer. 
Lambs were scored on the basis of post-challenge (PC) clinical signs and 
increase in rectal temperature. Lambs that had increase in rectal temperature and 
were off feed were scored as 1 while those with fever, nasal discharge, labored 
breathing and inappitance, were scored 2. Lambs with all the signs mentioned 
above and also had mouth breathing and reluctance to move, were given 3 scores. 
Blood samples were collected from each lamb on days 0,5,8,11,14, and 
21 PC. Serum was separated from each sample and stored at-20° C. Serum-
virus neutralization and HI tests were used to evaluate the immune response. 
Collection of nasal secretions 
Nasal secretions were collected from both nostrils of each lamb on day 0 
through day 8,11, and 14 using sterile cotton tipped polystyrene applicators. The 
applicators with nasal secretions were placed In sterile plastic tubes containing 2 ml 
of DMEM with 5% ovine serum, gentamicin sulfate (5 mg/100 ml), and antibiotic-
antimycotic solution (1 ml/100 ml, 10,000 units/ml penicillin G sodium, 10,000 
//g/ml streptomycin sulfate, and 25 yug/ml arriphotericin B in 0.85% saline, Gibco 
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Laboratories). These samples were held at 4°C in a cool box until transferred to 
an ultralow freezer and stored at -70 °C. 
Virus Isolation and Identification 
Cotton swabs containing nasal secretions and tracheal fluids (from 
necropsled lambs as described later) In DMEM were expressed against the side of 
the tube. Virus isolation was attempted by inoculating 0.3 ml of this suspension 
into a 25 cm^ tissue culture flask containing a subconfluent layer of OFT cells in 
DMEM with 10% ovine serum and gentamicin sulfate and antibiotic-antimycotic. 
The flasks were incubated at 37®C in an incubator and cells were examined daily 
for the presence of CPE. The presumptive isolation of OPI-3 virus was determined 
by the presence of CPE and/or adsorption and agglutination of 100 //I of 1% 
guinea pig red blood cells added to each flask. The isolated virus was compared 
with the challenge virus using Western immunoblot assay (WIA). 
Serum-virus neutralization test 
All the sera were heat inactivated at 56°C for 30 minutes. Virus 
neutralization (VN) antibody titers against OPI-3 virus were determined using a 
microtitration test. All samples were tested in duplicate. 
Two-fold dilutions (1:2 to 1:1024) of serum were made in DMEM and added 
(50 p\) to each well of a 96 well microtiter plate (Costar). Fifty //I of the test virus 
containing 100 TCIDgo, was added to each serum dilution. The serum-virus 
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suspensions were incubated at room temperature for 1 h. Fifty //I of OFT cells 
(grown in 150 cm^ flask, trypsinized and suspended in DMEM to make a final 
volume of 25 ml) were added in each well. This concentration of cells had 
previously been calculated to allow the Immediate formation of monolayer. The 
edges of the plates were sealed with paper tape to avoid evaporation and the 
plates incubated at 37 °C. A control plate with a positive and a negative serum 
against OPI-3 virus were also run at the same time. Test plates were read after 5 
days. The VN titer was determined as the reciprocal of highest dilution of serum 
which protected cells from viral CPE in 50% of the wells. 
Immunoperoxidase test 
Lung specimens collected from necropsied lambs (as described later) were 
cut to a thickness of 4 microns and fixed onto poly-L-lysine coated glass slides. 
These slides were fixed in acetone for 5 minutes and dried in air. Tissues were 
rehydrated by dipping these slides in deionized water for 5 minutes. A Vectastain-
ABC kit (Vector Laboratories, Burlingame, CA) was used for immunohistochemical 
staining. Slides were flooded with biotinylated anti-goat HPI-3 virus antibodies for 
20 minutes and then dipped in PBS for 10 minutes to remove excess antibodies. 
Avidin DH-biotinylated horseradish peroxidase H was overlayed on lung sections 
for further 20 minutes. Slides were again washed with PBS for 10 minutes. 
Substrate was added on the sections for about 3 minutes and then washed with 
103 
water. Slides were mounted and observed through a microscope for the presence 
of viral antigens in lung tissue. 
Bacterial isolation 
Swabs containing tracheal or lung fluid from necropsied lambs (as described 
later) were streaked onto blood and McConkey agar plates and incubated at 37°C 
for 24 to 48 h. Bacteria from different colonies were isolated. Routine 
bacteriological examinations and biochemical tests were performed for the 
identification of bacteria. 
Pathological findings 
One lamb from each group was euthanatized and necropsied on post-
challenge day 8. Tracheal fluids were collected on sterile cotton swabs and stored 
at -70°C. Lung specimens were collected using sterile scissors and forceps for 
virus isolation attempts. Tissues from lungs, trachea, turbinates and the 
mediastinal lymph node were collected and fixed in 10% formalin, embedded in 
paraffin, sectioned, and stained with hematoxylin and eosin (H&E) for 
histopathological evaluation. 
Statistical analysis 
A one way analysis of variance method with repeated measurements was 
used on SAS program to analyze data In present experimentation. 
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Experimental Procedures 
The experimental design for Experiment I is shown in Table 1. Animals were 
assigned to different groups based upon their HI titers against BPI-3 virus. Each 
lamb was injected with 1 ml of the vaccine preparation (500 //g/ml in Freund's 
incomplete adjuvant) subcutaneously (SO, 0.5 ml behind each ear). All the lambs 
including controls were boosted with 500 //g of BPI-3 virus vaccine, in Freund's 
incomplete adjuvant, at day 21 as described before. Blood samples (7 ml) were 
collected at day 0, 21 and 35 after primary immunization. The samples were 
allowed to clot and held at room temperature over night. The samples were 
centrifuged for 30 minutes at 2000 g for serum separation after which, the serum 
was allquoted and stored at -20°C. 
Table 1. Experimental design for ^periment I, indicating groups of lambs and 
vaccine administered." 
Primary Vaccination Secondary Vaccination 
Group Antibody Titer (500 uci) (500 PQ) 
(Range) No. Virus No. Virus 
A 2 - 1 6  20 Sendai 20 BPI-3 
B 2 - 1 6  20 HPI-3 20 BPI-3 
C 
CO 1 
CM 20 BPI-3 20 BPI-3 
D 2 -16 39 None 20 BPI-3 
® Lambs were randomly assigned to groups on the basis of BPI-3 virus antibody 
titers at the start of experimentation. 
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In Experiment II, lambs (4-6 weeks of age) were assigned to each of four 
groups so that each group had a distribution of lambs with equivalent HI titers 
against BPI-3 virus. Twelve lambs in each group were vaccinated with 25 fjq of 
virus protein (Table 2) while 12 were given 50 //g each (Table 3). Group A was 
immunized with Sendai virus, group 8 received HPI-3 virus, group C with BPI-3 
virus and group D remained as unvaccinated controls. All the lambs were boosted 
with BPI-3 virus (25 //g) on PID 21. Another group of 12 lambs served as 
unvaccinated controls. Blood samples (7 ml) were collected from lambs on PID 0, 
11,21,28, 35, and 46. Serum samples were prepared and stored at -20°C. 
Table 2. Experimental design for Experiment II, indicating groups of lambs and 
vaccine administered.® 
Antibody Titer Primary Vaccination Secondary Vaccination 
Group (Range) (25 jug) (25 //g) 
No. Virus No. Virus 
A 16 - 64 12 Sendai 12 BPI-3 
B 1 6 - 6 4  12 HPI-3 12 BPI-3 
C 16 - 64 12 BPI-3 12 BPI-3 
D 1 6 - 6 4  24 None 12 BPI-3 
® Lambs were randomly assigned to groups on the basis of BPI-3 virus antibody 
titers at the start of experimentation. 
Experiment III was a repetition of Experiment II except that it was conducted 
at a different farm. The experimental design was essentially the same but the 
number of lambs and the initial range of HI titers were different (Tables 4 & 5). 
Biood samples (7 ml) were collected on PID 0, 11, 21, 28, and 40. Serum samples 
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Table 3. Experimental design for Experiment II indicating groups of lambs and 
vaccine administered.® 
Group Antibody 
Titer 
Primary Vaccination 
(50//a) 
Secondary Vaccination 
(25 jua) 
(Range) No. Virus No Virus 
A 16-64 12 Sendai 12 BPI-3 
B 16-64 12 HPI-3 12 BPI-3 
C 16-64 12 BPI-3 12 BPI-3 
D 16-64 24 None 12 BPI-3 
® Lambs were ramdomly assigned to groups on the basis of anti-BPI-3 virus 
antibody titers at the start of experimentation. 
were prepared and stored at -20°C. Some of the lambs from each group were not 
vaccinated at day 21 in this experiment and were used in subsequent challenge 
experiment. 
Lambs selected during Experiment III for challenge with OPI-3 virus were . 
assigned to different groups. Lambs had previously served as nonvaccinated 
controls or had been vaccinated as indicated in Table 6. Vaccinated animals had 
received one or two doses of 25 //g of the respective virus protein. Group A lambs 
were vaccinated with two doses of BPI-3 virus (days 0 & 21), group B received 
BPI-3 virus (day 0 only), group C was immunized with HPI-3 virus (day 0 only), 
while group D served as unvaccinated controls. 
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Table 4. Experimental design for Experiment III, indicating groups of lambs and 
vaccine administered.® 
Antibody Titer Primary Vaccination Secondary Vaccination 
Group (Range) (25 PQ) (25 //g) 
No. Virus No. Virus 
A 4 - 6 4  18 Sendai 18 BPI-3 
B 4 - 6 4  18 HPI-3 10 BPI-3 
C 4 - 6 4  18 BPI-3 11 BPI-3 
D 2 - 6 4  37 None 18 BPI-3 
® Lambs were randomly assigned to groups on the basis of BPI-3 virus antibody 
titers at the start of experimentation 
Table 5. Experimental design for Experiment III indicating groups of larnbs and 
vaccine administered.® 
Antibody Primary Vaccination Secondary Vaccination 
Group , Titer (50 uq) (25 uq) 
(Range) No. Virus No. Virus 
A 4-64 9 Sendai 9 BPI-3 
B 4-64 9 HPI-3 9 BPI-3 
C 2-64 9 BPI-3 9 BPI-3 
D 0-64 37 None 18 BPI-3 
® Lambs were randomly assigned on the basis of antl-BPI-3 virus antibody titers at 
the start of experimentation. 
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Table 6. Experimental design for the challenge Infection experiment, indicating 
groups of lambs and vaccine administered.® 
Group No. Vaccination (25 //g) Antibody Titer 
(Range)*' 
A 5 BPI-3 (two doses) 32-128 
B 5 BPI-3 4 -16 
C 5 HPI-3 4-8 
D 5 None 4-8 
® Lambs were challenged with ovine PI-3 virus at day 46 post primary 
immunization. 
** Antibody titer at time of challenge. 
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RESULTS 
Viruses used in the experiments to immunize the animals were inactivated 
with BEI. An inactivation procedure was evaluated with BPI-3 virus and 
determination of infectious virus remaining at various time intentais. Absence of 
CPE and hemadsorption of guinea pig RBCs on MDBK cells indicated that BEI 
completely inactivated the virus in 8 h (Figure 1). Moreover, this inactivation was 
gradual, i.e., one log of virus/h. 
In Experiment I, all the lambs immunized with the different paramyxoviruses 
showed an increase in BPI-3 virus HI titer after primary immunization (Figure 2). 
However, lambs vaccinated with BPI-3 virus developed higher HI titers than the 
other groups. A minimal immune response was recorded in lambs immunized with 
Sendai virus. A further increase in HI titer was noted after the booster at day 21 
but the pattern of antibody titers remained the same. Also, the immune response 
induced by Sendai virus vaccination was not significantly different from the controls 
at day 35 as determined by an analysis of variance (ANOVA) test (P= 0.6395). 
In a subsequent experiment, different vaccine doses of BPI-3 virus were 
evaluated to determine the quantity of virus required to induce an immune 
response in lambs having a low maternal antibody titer. All four doses proved to 
be immunogenic in lambs (Figure 3) but the response was dose dependent. The 
responses were highest on day 20 post immunization and had declined by day 34. 
Figure 1. Bovine PI-3 virus was treated with BEI. Samples were collected at 
hourly intervals and inactivation rate was determined by Infectivity for 
OFTU cells. 
Figure 2. Mean Logg anti-BPI-3 virus antibody titers of lambs in Experiment I at 
intervals following immunization with one of several paramyxoviruses 
at day 0 and BPI-3 at day 21. The groups and primary immunization 
were as follows: A- Sendai virus; B- HPI-3 virus; C- BPI-3 virus and D-
nonvaccinated controls. 
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Figure 3. Mean Logg anti-BPI-3 virus HI antibody titers of groups of lambs at 
intervals following immunization with different doses of BPI-3 virus at 
day 0. The doses were 25, 50, 100 and 200/wg. 
Figure 4. Mean Logg anti-BPI-3 virus HI antibody titers of groups of lambs in 
Experiment II following immunization with one of several 
paramyxoviruses at day 0 and BPI-3 virus at day 21. Groups and 
primary immunization were as follows: A- Sendai virus; B- HPI-3 virus; 
C- BPI-3 virus; D- nonvaccinated controls. 
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Based upon these results, two doses of virus, i.e., 25 uq and 50 //g were used to 
immunize lambs in later experiments. 
Results of Experiment II are shown in Figure 4. 
Following primary immunization with 25 jug doses of the vaccines, the 
antibody titers had declined by day 21. All groups responded with an increase in 
HI titer after a booster dose at day 21. On day 28, the highest response was 
observed in group C lambs followed by groups B and A. Statistical analysis 
(ANOVA) indicated that the mean HI titer values of group C lambs was significantly 
higher (P=0.0492) than that of the other groups. But on day 35, there was no 
significant difference in HI titers of lambs in groups B and C. The pattern was 
almost same at day 46. Also, it was evident that the titer of serum of lambs 
immunized with Sendai virus vaccine did not differ significantly from controls. 
However, the HI titer of lambs in the control group remained significantly lower than 
that of groups B and C. 
HI titers of lambs immunized with 50 //g virus dose in Experiment II are 
shown in Figure 5. 
Although the dose was higher, antibody responses among groups were 
similar to lambs that received a 25 //g dose. All groups showed a decline in HI titer 
on day 21. After a booster dose, all groups responded with an increase in HI titer. 
The highest response was observed on day 28 in group C lambs followed by 
groups B and A on day 28. However, HI titer of group B lambs was higher but not 
significantly different from group C on day 35. The HI titer of groups B and C 
Figure 5. Mean Logg anti-BPI-3 virus HI antibody titers of groups of lambs in 
Experiment II at intervals following primary immunization with 50 //g of 
one of several paramyxoviruses at day 0 and BPI-3 virus (25 fjg) at 
day 21. Groups and primary immunization were as follows: A- Sendai 
virus; B- HPI-3 virus; C- BPI-3 virus; and D- nonvaccinated control. 
Figure 6. Mean LoQj anti-BPI-3 virus HI antibody titers of groups of lambs in 
Experiment III following immunization with a 25 fjg dose of one of 
several paramyxoviruses at day 0 and BPI-3 virus at day 21. Groups 
and primary immunization were as follows: A- Sendai virus; B- HPI-3 
virus; C- BPI-3 virus; and D- nonvaccinated control. 
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lambs was not significantly different but was significantly higher than groups A and 
D on day 46. 
Experiment III was a replication of Experiment II at a different farm. Maternal 
antibody titers at the time of primary immunization were lower than of lambs in 
Experiment II. Mean antibody titers of groups of lambs immunized with 25 //g 
doses of vaccine are shown in Figure 6. 
Antibody titers decreased in all groups following primary immunization but 
was minimal in group C. All groups developed increased levels of antibody after 
the booster dose of vaccine on day 21 but the rise was most dramatic in group C. 
This increase in HI titer was significantly higher than that of other groups at day 28 
but there was almost no difference in the HI titers of lambs in groups B and C at 
day 40. There was no significant difference in the HI titers of lambs in groups A 
and D after the booster dose at day 21. 
Responses of lambs vaccinated with 50 //g of virus in Experiment III are 
shown in Figure 7. 
By day 21, mean antibody titers in groups B and C were essentially 
equivalent to the titers at 0 day. All groups responded to immunization at day 21 
with the highest titers in groups B and C at 28 and 40 days. The response of 
Sendai virus primed lambs was essentially the same as the group D controls. 
While the responses of group B and C lambs at 21 days were higher than lambs 
vaccinated with 25 //g of virus, there was essentially no difference in the titers 
following booster immunization. 
Figure 7. Mean Logg anti-BPI-3 virus HI antibody titers of groups of lambs in 
Experiment III at intervals following primary immunization with 50 //g of 
one of several paramyxoviruses at day 0 and BPI-3 virus (25 /jg) at 
day 21. Groups and primary immunization were as follows: A- Sendai 
virus; B- HPI-3 virus; C- BPI-3 virus; D- nonvaccinated control. 
Figure 8. Mean Logg anti-HPI-3 virus HI antibody titers of groups of lambs in 
Experiment III immunized at day 0 with HPI-3 virus (25 //g) and at day 
21 with BPI-3 virus (25 JJQ). 
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In Experiment III, serums from lambs vaccinated Initially with HPI-3 virus 
(25 jt/g) and secondarily with BPI-3 virus were tested for the level of antibodies 
against both viruses in HI tests. While antibody levels for BPI-3 virus declined at 11 
days, at the same time there was an increse in the level of HPI-3 virus HI 
antibodies (Figure 8). 
Titers to both viruses Increased following secondary vaccination by BPI-3 
virus, with titers to BPI-3 virus increasing most dramatically. 
Data derived from the HI antibody responses of lambs in Experiment III was 
also evaluated based upon pre-vaccination antibody levels. Lambs were assigned 
to two groups according to their HI antibody titers against BPI-3 virus at day 0, i.e., 
:s8 and ^16, to observe the effect of vaccine virus in inducing antibody responses 
in the presence of different levels of maternal antibodies. Maternal antibodies in 
lambs with lower titers (^8) did not block the effect of vaccination with BPI-3 virus 
completely as indicated by increase in HI titers after Immunization (Figure 9). 
Another interesting obsen/ation was the significant Increase in HI titers after booster 
vaccination in lambs primarily vaccinated with Sendai virus. Lambs with an initial 
high titer (^16) of antibodies did show a decline in HI titers after primary 
vaccination as shown in Figure 10. Lambs in group A did not show any change in 
HI titers after booster, whereas, lambs in groups B, C, and D did develop some 
increase in HI titers after vaccination with BPI-3 virus at day 21. 
Lambs originally included in Experiment III were selected for challenge with 
live ovine PI-3 virus. All the lambs showed a rise in rectal temperature following 
Figure 9. Mean Logs anti BPI-3 virus HI antibody titers of groups of lambs in 
Experiment III following immunization with one of several 
paramyxoviruses (25 //g each) at day 0. These lambs had HI 
antibody titers ^6 at the time of primary vaccination. BPI-3 virus (25 
JJQ) was administered at day 21 to 12,4,6 and 10 lambs from groups 
A, B, C and D respectively. Groups and primary immunization were 
as follows: A- Sendai virus; B- HPI-3 virus; C- BPI-3 virus; D-
nonvaccinated control. 
Figure 10. Mean Logg anti-BPI-3 virus HI antibody titers of lambs in Experiment 
III following immunization with one of several paramyxoviruses (25 //g 
each) at day 0. These lambs had HI titers 5:16 at the time of primary 
immunization. BPI-3 virus (25 //g) was administered at day 21 to 6 
lambs each from groups A, B, and C and 13 lambs from group D. 
Groups and primary immunization were as follows: A- Sendai virus; B-
HPI-3 virus; C- BPI-3 virus; D- nonvaccinated control. 
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Figure 11, Mean rectal temperature of groups of lambs following challenge with 
an ovine strain of PI-3 virus. Groups of Iambs and previous 
treatments were as follows: A- primary and secondary immunization 
with BPI-3 virus; B- primary Immunization with BPI-3 virus only; C-
primary immunization with H PI-3 virus only; and D- nonvaccinated 
control. 
Figure 12. Mean clinical scores of groups of lambs following challenge with an 
ovine strain of PI-3 virus. Groups of lambs and previous treatments 
were as follows: A- primary and secondary immunization with BPI-3 
virus; B- primary Immunization with BPI-3 virus only; C- primary 
immunization with HPI-3 virus; and D- nonvaccinated control. 
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challenge exposure but the duration and severity varied (Figure 11). The 
meanrectal temperature was highest in all the lambs on day 4 post-challenge (PC). 
Control lambs developed the greatest temperature response and the increase in 
mean rectal temperatures persisted for a longer period of time than other groups. 
The temperature response of lambs in group B was also higher than groups A and 
C and persisted longer. Rectal temperatures of lambs in group A did not increase 
dramatically until day 3, peaked at day 4, and returned to normal by day 7 PC. 
A similar pattern was observed when lambs were scored on the basis of 
their clinical signs (Figure 12). Lambs In group D showed clinical disease earlier 
and were most severely affected with depression, Increase in respiration rate, 
labored breathing and inappetence. Clinical signs persisted for a longer period 
than for other groups. Clinical disease developed later in the vaccinated groups 
(day 3), were most prominent on days 5 and 6 and diminished by day 7 PC. 
Results of virus isolation from nasal swabs obtained at ihten/als following 
challerige are shown in Table 7. Virus was isolated from all lambs on days 1-5 
(days 2-4 not included in Table 7) but thereafter the duration of virus shedding was 
variable among the groups. Virus was not isolated from lambs in groups A and C 
on day 8 PC whereas groups B and D were negative for virus shedding on day 11 
and 14 respectively. 
Virus isolated from lambs in different groups was used to prepare antigen 
for a Western immunoblot assay (WIA). A comparison with the virus used for 
challenge indicated that the viruses possessed a similar pattern of proteins. 
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Table 7. Virus Isolation from lambs following challenge with OPI-3 virus. Nasal 
swabs were collected from each lamb on the days indicated and clarified 
supernatant fluids inoculated onto OFTU cell monolayers for virus isolation. 
Groups of lambs and previous treatment were as follows: A- primary and 
secondary immunization with BPI-3 virus; B- primary immunization only with BPI-3 
virus; C- primary immunization only with HPI-3 virus; D- nonvaccinated controls. 
Days after Challenge 
0 2 5 6 7 8 11 14 
GROUPS 
A 0/0® 5/5 5/5 4/5 2/5 0/5 0/4 0/4 
B 0/0 5/5 5/5 5/5 5/5 4/5 0/4 0/4 
C 0/0 5/5 5/5 5/5 2/5 0/5 0/4 0/4 
D 0/0 5/5 5/5 5/5 5/5 5/5 3/4 0/4 
® Number animals yielding virus/Total animals tested. 
Serum samples collected from lambs following challenge were tested for HI 
antibodies. All the lambs developed increased levels of antibodies to BPI-3 virus 
after challenge (Figure 13). Slight increases in titer were noted on day 5 and the 
rise was marked by day 8 in the vaccinated groups of animals. Non-vaccinated 
controls were slower to respond and the mean titers did not approach levels in 
vaccinated animals. 
Serums were also assayed for virus neutralizing activity. Figure 14 shows 
the results of virus neutralization tests. An increase in serum antibodies was 
detected at day 5 with a dramatic rise in titer in the vaccinated animals by day 8. 
There was a limited increase in levels of neutralizing antibody titers in vaccinated 
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animals after day 8 while levels in non-vaccinated controls continued to Increase up 
to day 21. 
Bacterial examination was performed on the tracheal fluid of lambs 
necropsied on day 8 PC. Pasteurella hemolvtica and Corvnebacterium pvoaenese 
organisms were isolated from tracheal fluid and abscess material respectively of 
the lamb in group D. Pasteurella multoclda was Isolated from the tracheal fluid of 
the lamb in group B. No bacteria could be isolated from lambs in groups A or C. 
Figures 15 to 18 illustrate the gross lesions observed in lungs of lambs in 
different groups after challenge with OPI-3 virus. Massive abscessation and 
bronchopneumonia was observed in both lungs of the lamb in group D. The 
cranio-dorsal region of right and left lobes showed severe consolidation with 70% 
of the lobes affected. Massive congestion of both lungs (50%) of the lamb in 
group B was noted and consolidation of right cranial and middle lobes was seen. 
Minimal congestion and consolidation (10%) was observed in cranial and middle 
lobes of the right lung and small part of the left cranial lobe of lamb in group C. 
Lungs of lamb in group A looked normal. However, few streaks of congestion on 
the right cranial lobes were seen. 
Lung tissues of the control lamb showed multifocal subacute suppurative 
bronchopneumonia with several centers of necrosis and hemorrhage. There were 
large areas of consolidation with accumulation of fibrin, edema fluid and 
inflammatory cells, primarily neutrophils (Figures 19 & 20). 
Figure 13. Mean Logg anti-BPI-3 virus HI antibody titers of groups of lambs after 
challenge with an ovine strain of PI-3 virus. Groups of lambs and 
previous treatments were as follows: A- primary and secondary 
immunization with BPI-3 virus; B- primary immunization with BPI- 3 
virus only; C- primary immunization with HPI-3 virus only; and D-
nonvaccinated control. 
Figure 14. Mean Log; anti-BPI-3 virus VN antibody titers of lambs after challenge 
with an ovine strain of PI-3 virus. Groups of lambs and previous 
treatments were as follows: A- primary and secondary immunization 
with BPI-3 virus; B- primary immunization with BPI-3 virus only; C-
primary immunization with HPI-3 virus only; and D- nonvaccinated 
control. 
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Figure 15. (Top Left) Lungs of a lamb vaccinated with two doses of BPI-3 virus. 
The lamb was necropsied at day 8 PC. Few streaks of congestion 
are seen only on right cranial lobe. 
Figure 16. (Top Right) Lungs of a lamb vaccinated with single dose of BPI-3 
virus. The lamb was necropsied at day 8 PC. Marked areas of 
consolidation on right and left cranial and middle lobes and more 
limited reactions in the caudal lobes was noted. 
Figure 17. (Bottom Left) Lungs of a lamb vaccinated with single dose of HPI-3 
virus. The lamb was necropsied at day 8 PC. Some area of the 
cranial and middle lobes of right and left side was consolidated. 
Figure 18. (Bottom Right) Lungs of a nonvaccinated lamb after challenge with 
OPI-3 virus. The lamb was necropsied at day 8 PC. Colored area 
indicates massive consolidation and abscessation in many areas of 
both lungs. 
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Most airways and alveoii in consolidated areas were also filled with 
neutrophils. Some hyperplasia of bronchiolar epithelium in these areas was also 
seen (Figure 21). 
A few bacterial colonies were observed in necrotic areas of lungs from the 
nonvaccinated lamb. This is typical of early pneumonia caused by Pasteurella 
hemolytica. There was also a diffuse interstitial pneumonitis around small airways 
with thickening of septa infiltrated with mononuclear cells and fewer neutrophils 
(Figure 22). 
Bronchiolar epithelium was intact but missing cilia and was generally 
covered by a layer of neutrophils. The lymph node was active but edematous and 
had an extensive accumulation of neutrophils in sinusoids. Large areas with loss of 
cilia and squamous to cuboidal metaplasia of the epithelium was observed in 
trachea. There was an occasional neutrophil in the epithelium. The turbinates 
were normal in this lamb. 
Lungs of the lamb in group B were similar to those of the lamb in group D, 
but without necrotic centers or hemorrhage. The lymph node appeared active and 
normal. Some loss of cilia and flattening of surface cells were noted in tracheal 
tissue. A few neutrophils in epithelium of this tissue area were seen. Turbinate 
tissue was also normal. 
A diffuse interstitial inflammation (pneumonitis) consisting of accumulation of 
mononuclear cells along with alveolar collapse (atelectasis) was observed in the 
lungs of lamb from group C (Figure 23). 
Figure 19. Photomicrograph of a section of lung of nonvaccinated lamb 
challenged with OPI-3 virus. Neutrophil infiltration, fibrin deposition, 
and macrophages are seen in alveoli. 
Figure 20. Photomicrograph of a section of lung of a nonvaccinated lamb 
challenged with OPI-3 virus. Neutrophils and macrophages fill alveoli. 
Type il pneumocytes (arrow) are common throughout the section. 
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Figure 21. Pliotomicrograph of a section of lung of nonvaccinated lamb, 
challenged with OPI-3 virus. The bronchiole with mild hyperplasia and 
distended with neutrophils is noted. Surrounding alveoli have diffuse 
neutrophil infiltration. 
Figure 22. Photomicrograph of a section of OPI-3 virus infected lung of 
nonvaccinated lamb. Peribronchiolar interstitial areas thickened due 
to infiltration of inflammatory cells. 
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There were very few neutrophils in this lung. In trachea of the lamb from 
group C, there was extensive loss of cilia and accumulation of mononuclear cells, 
primarily lymphocytes, were recorded in the lamina propria and, to a lesser extent, 
in the epithelium (Figure 24). 
The turbinates were normal except for a minor mononuclear cell infiltrate. 
The lymph node was normal. 
Lung tissues of the lamb in group A were similar to those in group B lambs 
with some hemorrhage but less extensive. Increased amounts of bronchous 
associated lymphoid tissue (BALT) with some lymphoid follicles was noted in this 
lung. The lymph node was normal and active. Tracheal epithelium was missing 
(possibly an artifact). Foci of mononuclear cell infiltrates were observed in the 
lamina propria and epithelium. Turbinate tissue appeared normal except there was 
Infiltration of a few mononuclear cells. 
Figure 23, Photomicrograph of a section of OPI-3 virus infected lung of lamb 
immunized with single dose of HPI-3 virus. Alveoli are collapsed and 
peribronchiolar alveoli contain neutrophils and macrophages. 
Figure 24. Photomicrograph of a section of trachea of lamb immunized with 
single dose of HPI-3 virus vaccine and challenged with OPI-3 virus. 
Tracheitis with loss of cilia on tracheal epithelium and extensive 
migration and sub-epithelial accumulation of inflammatory cells, 
predominantly neutrophils and lymphocytes are present. 
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DISCUSSION 
Antigenically related animal viruses have been used for immunization of 
various species against viral diseases. Vaccinia virus, a bovine (Vesakari et al., 
1984) and a simian (Flores et al., 1987) rotavirus, and reassortant influenza viruses 
bearing avian influenza-A virus genes (Murphy et al., 1985) have each been shown 
to be attenuated and Immunogenic in humans and have induced resistance to 
natural or experimental infection with wild type human viruses. In animals, measles 
virus vaccine has been successfully used to immunize young dogs against canine 
distemper virus Infection in the presence of maternal antibodies (Appel et al., 1984). 
With these encouraging precedents in mind, we sought to examine the potential 
usefulness of BPI-3, HPI-3 and Sendai viruses as vaccines to protect young lambs 
against infection with a strain of PI-3 virus capable of producing disease. 
In these studies, BEI was used to inactivate the viruses for the preparation 
of vaccines. In vitro assays for infectivity, together with the absence of any 
seroconversions in control lambs which cohabited with vaccinated animals, 
provided reliable evidence that the vaccine viruses had been fully inactivated. 
Hurst, (1957), Girard et al. (1977), Makarasen et al. (1985), Park et al. (1985) 
Buonavoglia et al. (1988) and Bahnemann, (1990) were of the opinion that viral 
vaccines prepared with BEI as the inactivant were antigenically superior to those 
inactivated with formaldehyde. The results of HI tests in the present studies 
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indicated that the envelope proteins of viruses retained their antigenicity after 
Inactivation with BEI. 
An objective of the present study was to evaluate the immune response 
induced by different paramyxoviruses in lambs in the presence of maternal 
antibodies. Maternal antibody titers of the lambs at the start of the experimentation 
were quite variable and did not correlate well with age. Also, the titers were 
moderate and not as high as was expected. Some animals possessing higher 
antibody titers would have facilitated the experimentation. 
Animals in Experiment I responded to all virus vaccines with an increase in 
antibody titers to BPI-3 virus although the response to Sendai virus was minimal. 
These results were not expected but were apparently due to the large quantity of 
virus incorporated in a Freund's incomplete type adjuvant. It also indicated that a 
large quantity of virus, although economically impractical, was capable of 
overcoming the suppressive effects of the relatively low level of maternal antibodies 
present in these lambs. In Experiments II and III, comparatively small doses of 
vaccine virus were used in aluminum hydroxide to Immunize the lambs. In these 
experiments, we were able to demonstrate the blocking of vaccine virus antigens 
by maternal antibodies present in the lambs. Although the HI titers dropped 
following vaccination, all three viruses sensitized the lambs as determined by the 
immune response after boosting. The response was appreciably higher in lambs 
vaccinated with HPI-3 virus than that with Sendai virus. These results suggested 
that BPI-3 and HPI-3 viruses are antigenically more closely related. This statement 
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was further supported by the results when HI antibody titers of lambs immunized 
with HPI-3 virus and BPI-3 virus in Experiment III were determined using 
homologous virus in HI tests. Lambs responded with an increase in HI titers 
following vaccination with HPI-3 virus. Thus HPI-3 viral antigens were not 
completely neutralized by the PI-3 virus maternal antibodies present in the lambs. 
This indicated that, although HPI-3 and BPI-3 viruses are antigenicaliy related, there 
are some differences as reported also by other workers (Coelingh et al., 1986; Ray 
and Compans, 1986; Rydbeck et al., 1987; Klippmark et al., 1990). These 
differences in the neutralizing epitopes may play a crucial role in inducing immune 
response in the presence of maternal antibodies. 
The role of maternal antibodies in blocking the response to vaccine virus 
was further strengthened when the immune response in lambs with low (^8) and 
high (^16) prevaccination HI titers was evaluated. Low levels of maternal 
antibodies did not completely neutralize the antigenicity of BPI-3 virus vaccine and 
there was an appreciable increase in the response by all vaccinated lambs 
following boosting. However, higher levels of maternal antibodies did block the 
primary reponses to vaccine virus and secondary immunization failed to elicit an 
appreciable increase in the antibody titers. 
Immune responses against attenuated or inactivated BPI-3 virus has been 
evaluated by many workers using HI tests (Rodger, 1989; Koves et al., 1982; 
Coelingh et al., 1988). They observed an increase in HI antibody titers following 
vaccination. However, those findings cannot be compared since the level of 
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maternal antibodies at tlie time of Immunization, the amount of virus, and the type 
of adjuvant used to immunize the animals varied. Rodger, (1989) did observe a 
drop In HI titers, or no response In some lambs after vaccination. It could be 
postulated that presence of maternal antibodies did interfere with the vaccine virus 
in some of the lambs following vaccination. 
The presence of serum antibodies in the challenge lambs was not an 
absolute indication of protection. The group of lambs immunized with two doses of 
BPI-3 virus vaccine had a moderate level of HI antibody titers at the time of 
challenge but still sufferred some clinical Illness and shed virus. Also, the group of 
lambs receiving a single dose of HPI-3 virus vaccine possessed very low level of HI 
antibody titers but the clinical disease was similar to the group that received two 
doses of BPI-3 virus vaccine. It is interesting that two groups of lambs (twice BPI-3 
virus and single HPI-3 virus vaccinates) with some levels of VN antibody titers at 
the time of challenge were somewhat protected as Indicated by a moderate 
disease process. According to Frank and Marshall, (1971), the degree of 
protection primarily depends on the antibody concentration in nasal secretions, 
while the severity and course of the disease reflects the level of the serum 
antibodies. It has also been postulated that in case of high VN antibody titers in 
the serum, antibodies might be exudated into the nasal secretion (Marshall and 
Frank, 1971). Others have reported a definite protective effect of inactivated 
vaccines in calves (Probert et al., 1978) and lambs (Wells et al., 1978) with high 
serum antibody titers elicited by the vaccines. Spriggs et al. (1987) utilized HN and 
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F proteins of HPI-3 virus to immunize cotton rats. They did not see any correlation 
between serum antibody titers and protection of cotton rats after challenge with 
HPI-3 virus. It was concluded that immune mechanisms other than serum 
antibodies make important contributions to resistance against infection. 
Following challenge exposure, the virus was isolated from the nasal 
secretions of all the lambs up to day 11 PC. However, the viral clearance was 
more efficient from lambs in groups A and C than those in groups B and D. 
Previous studies have reported similar results where virus was isolated during a 7 
day period of observation PC (Wells et al., 1976; Lehmkuhl and Cutlip, 1983). 
The gross pathological findings in lambs from different groups varied in 
severity. Lesions were much more extensive in lungs of Lambs that were not 
vaccinated (group D) or vaccinated with a single dose of BPI-3 virus (group B) than 
in lungs from groups A and C (twice BPI-3 virus and single HPI-3 virus vaccinates 
respectively). These lesions are typical of those reported by other workers (Sharp 
et al., 1978; Davies et al., 1981). The lesions included congestion, consolidation, 
and bronchopneumonia. The lesions in experimentally infected lambs have also 
been described by other researchers. Hore and Stevenson, (1969) observed 
multiple areas of consolidation in all lobes of lungs; These lesions are similar to 
those of lambs in this experimentation. Microscopically, the pathological alterations 
also varied in lambs from different groups. The lesions observed were consistent 
with those reported by Hore and Stevenson, (1969), Stevenson, (1969), Sing et al. 
(1977) and Cutlip and Lehmkuhl, (1982). These lesions have been reported to be 
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associated with damage caused by Pasteurella hemolvtica in lambs (More and 
Stevenson, 1969; Cutlip and Lehmkuhl, 1982); goats (Stevenson and More, 1970; 
Frank and Marshall, 1973; Afshar and Terleckl, 1979) and calves (Palotay and 
Newhall, 1958; Jubb et al., 1985). Although these authors have not related the 
lesions with the immunization of animals, the lesions noted in experimentally 
infected animals were comparable to those in our studies. 
Extensive lesions were observed in those lungs also infected with Pasteurella 
hemolytica and Corynebacterium pyoaenese or Pasteurella multocida (groups D 
and B respectively). Previous reports have indicated that PI-3 virus alone can 
produce lung lesions in lambs and goats (Davies et al., 1983; Lehmkuhl and Cutlip, 
1982). However, Davies et al. (1981) observed extensive pneumonic lesions in 
lambs only when PI-3 virus was inoculated along with Pasteurella hemolytica. 
Whether the lungs lesions observed in present study were primarily associated with 
PI-3 virus Infection or were the result of secondary bacterial infections Is not clear. 
Results of this experimentation indicated that immunization of lambs with 
H PI-3 virus has some potential of protecting these animals from infection against 
PI-3 virus. Also, there are indications that this viral vaccine may overcome a 
moderate level of maternal antibodies against PI-3 virus. This is obvious by the rise 
in antibody titers following immunization and the capacity of single dose of H PI-3 
virus vaccine to provide some protection in lambs from a challenge exposure. 
Consequently, this heterotypic approach to vaccination of young lambs should be 
explored further. The selection of an appropriate strain of H PI-3 virus. 
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determination of suitable dosage and a schedule of immunization should be 
evaluated. There is promise that appropriate vaccination could induce immunity in 
the presence of maternal antibodies that would reduce the occurrence of clinical 
disease of lambs exposed to virus in the field. 
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GENERAL SUMMARY 
In present studies, polyclonal antiserums were raised against several 
paramyxoviruses in lambs and utilized to study antigenic relationships between the 
viruses. The viruses selected for investigation were bovine PI-3 (BPI-3), human 
PI-3 (HPI-3), Sendai and simian virus-5 (SV-5). Various assays used to evaluate 
the antiserums included hemagglutination inhibition (HI) test, enzyme linked 
immunosorbent assay (ELISA), Western immunoblot assay (WIA), and 
radiolmmunopreclpltation assay (RIPA). Results of these studies indicated that 
BPI-3 and HPI-3 viruses are closely related antigenically; Sendai virus shared 
several epitopes with these viruses but an SV-5 relationship was only indicated in 
association with the NP proteins. 
Results of HI tests demonstrated that the HN proteins of BPI-3 and HPI-3 
viruses share some common epitopes. Minimal differences in HI titers were 
observed with serums against BPI-3 and HPI-3 viruses in homologous as well as 
heterologous reactions. 
The ELISA results demonstrated that both the strains (bovine and human) of 
parainfluenza virus are highly crossreactive. Although the results of HI tests and 
ELISA were comparable, there were some discrepancies. In ELISA, HPI-3 virus 
antiserum showed lower reactivity against BPI-3 virus than in HI tests. Also, BPI-3 
and HPI-3 viruses antiserums reacted against Sendai virus in ELISA but this 
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reactivity was not reciprocated. It is possible that antibodies of differing affinities 
did not adhere strongly with viral antigens and thus were not detected in ELISA. 
In WIAs and RIPAs, BPI-3 and HPI-3 antiserums recognized P, HN, NP, F 
and M proteins in homologous as well as heterologous systems. This 
crossreactivlty had previously been demonstrated for HN, NP, F and M proteins by 
Rydbeck et al. (1987) using MAbs against HPI-3 virus proteins in RIPA. 
Antigenic relationships between Sendal virus and PI-3 viruses were also 
demonstrated. These viruses apparently share common antigens associated with 
their HN proteins as indicated by HI and ELISA results. However, one way 
crossreactivlty was observed between Sendai virus antiserum and the HN protein 
of BPI-3 virus in WIA. In RIPA, We were able to demonstrate the reactivity of 
Sendai virus antiserum with P, HN, NP, F and M of HPI-3 virus but no reactivity 
was observed with BPI-3 virus. 
In RIPA, antiserums against BPI-3 and HPI-3 viruses precipitated NP protein 
of all the viruses. Conserved regions in-NP protein probably reflect a common 
protein function in each of these paramyxoviruses. For example, Deshpande and 
Portner, (1985) reported two epitopes on the NP protein of Sendai virus that were 
associated with the transcriptional activity during viral replication. 
Limited crossreactivlty was observed between SV-5 and other viruses in HI 
tests, ELISAs, WIAs and RIPAs. BPI-3 and HPI-3 viruses antiserums precipitated 
the NP protein of SV-5 in RIPA. The reactivity of SV-5 antiserum was also limited to 
NP protein of HPI-3 virus only. 
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Polyclonal antiserums in present studies demonstrated the sharing of 
crossreactive epitopes among BPI-3, HPI-3 and Sendai viruses. Results of this 
experimentation suggest that there may be potential for these viruses to be applied 
in heterotypic immunization. This approach might be utilized to overcome the 
antigen blocking effect of maternal antibodies against PI-3 virus in lamb. 
Based upon the results of this experimentation, we designed experiments to 
observe the immunogenicity of BPI-3, HPI-3 and Sendai viruses in the presence of 
different levels of maternal antibodies against PI-3 virus in young lambs. Maternal 
antibody titers of the lambs at the start of experimentation were quite variable and 
did not correlate well with age. Also, the titers were moderate and not as high as 
was expected. Some animals possessing higher antibody titers would have 
facilitated the experimentation. 
Viruses were inactivated with binary ethyleniminé (BEI) to prepare the 
various vaccines. In Experiment I, a large quantity of semi-purified virus was 
incorporated in an oil adjuvant and each lamb was administered 500 //g of 
respective virus vaccine. Lambs in all groups responded to vaccination with an 
increased titer of antibodies to BPI-3 virus. This was not expected but was 
apparently due to the large quantity of virus incorporated in a Freund's type 
adjuvant. However, it is apparent that a large quantity of virus, although 
economically impractical, is capable of overcoming the suppressive effects of 
maternal antibodies. 
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Subsequently, an experiment was conducted to find out minimum dose of 
virus that would induce an immune response in lambs in the presence of a low 
level of maternal antibodies. The results indicated that BPI-3 virus dose as low as 
25 fjq was potentially immunogenic. So, in further studies, vaccines containing 
either 25 or 50 //g of virus protein in aluminum hydroxide were used. 
Results of Experiment II indicated that presence of maternal antibodies did 
block the immune response in all groups of lambs after vaccination. However, 
immune responses were significantly higher after a booster dose (BPI-3 virus, 
25 //g) in lambs vaccinated with either BPI-3 or HPI-3 viruses. The HI titers of 
lambs vaccinated with Sendai virus were comparable to those in the control group. 
These results confirm previous observations that HPI-3 virus does share antigenic 
crossreactivity with BPI-3 virus and that it can prime the animal in the presence of 
maternal antibodies against PI-3 virus. However, it is speculated that there is not 
much potential for Sendai virus vaccine to be used against PI-3 virus infection in 
young lambs. 
Experiment III was a replication of Experiment II and was conducted at a 
different farm. Results of HI tests demonstrated a similar pattern as was recorded 
in Experiment II. In both these experiments, HI titers of lambs vaccinated with 
either 25 /vg or 50 //g were not significantly different. 
Lambs selected during Experiment III for challenge with ovine PI-3 (OPI-3) 
virus were assigned to different groups. The lambs were vaccinated with 25 //g of 
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either BPI-3 virus (one or two doses), HPI-3 virus (single dose) or had previously 
served as nonvaccinated controls. 
All the lambs developed clinical signs of disease and increased rectal 
temperatures following challenge exposure. The most pronounced effects were 
observed in unvaccinated control lambs whereas, lambs vaccinated with two doses 
of BPI-3 virus or a single dose of HPI-3 virus showed moderate signs of illness. 
Lambs vaccinated with a single dose of BPI-3 virus did not show much protection 
against the challenge virus. 
Virus was isolated from the nasal secretions of all the lambs but the duration 
of virus shedding was variable in different groups. Early clearance of virus in lambs 
vaccinated with two doses of BPI-3 virus or a single dose of HPI-3 virus suggested 
the induction of a better secondary immune response. 
Results of HI and virus neutralization (VN) tests indicated increases in serum 
antibody levels following challenge. The titers were significantly higher in lambs 
vaccinated with either two doses of BPI-3 virus or a single dose of HPI-3 virus as 
compared with the control group. It was also observed that VN antibody titers 
were better correlated with the protection of lambs than were the HI titers. 
One lamb from each group was necropsied on day 8 following challenge. 
Observation of pathological changes in the respiratory tract provided direct 
evidence of the level of protection. The gross and histopathologlcal findings varied 
in severity from animal to animal depending upon the immunization protocol. The 
lesions included congestion, consolidation and bronchopneumonia. Massive 
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consolidation and abscessation were observed in the lungs of the control lamb 
whereas there were only a few streaks of congestion in the lungs of the lamb 
vaccinated with two doses of BPI-3 virus. Small areas of consolidation were 
present in the lungs of the lamb vaccinated with single dose of HPI-3 virus. The 
lungs of lamb vaccinated with single dose of BPI-3 virus showed extensive 
pathologic alterations indicative of minimal resistance induced by vaccine. 
Immunization with the HPI-3 virus in the presence of maternal antibodies, 
followed by challenge infection using OPI-3 virus induced high antibody titers to 
BPI-3 virus, a result Indicating that a booster antibody response develops after 
heterologous virus challenge. It is possible that a schedule of immunization with 
HPI-3 virus could be developed that would induce sufficient immunity in the 
presence of maternal antibodies to restrict replication of PI-3 virus and greatly 
reduce the occurrence of serious disease in young lambs. The present findings 
provide a basis for evaluating the heterologous PI-3 virus of human origin as an 
inactivated virus vaccine in young lambs and calves. 
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